Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Inflammatory Bowel Diseases

  Free Subscription


Articles published in J Crohns Colitis

Retrieve available abstracts of 453 articles:
HTML format



Single Articles


    November 2022
  1. EL-ZIMAITY H, Shaffer SR, Riddell RH, Pai RK, et al
    Beyond Neutrophils for predicting relapse and remission in ulcerative colitis.
    J Crohns Colitis. 2022 Nov 25:jjac178. doi: 10.1093.
    PubMed     Abstract available


  2. KONTOLA K, Oksanen P, Huhtala H, Jussila A, et al
    Increasing incidence of inflammatory bowel disease with greatest change among the elderly: a nationwide study in Finland, 2000-2020.
    J Crohns Colitis. 2022 Nov 24:jjac177. doi: 10.1093.
    PubMed     Abstract available


  3. FIOCCHI C, Iliopoulos D
    Numbers Do Not Lie: The Dire Need for New Directions in IBD.
    J Crohns Colitis. 2022;16:1649-1650.
    PubMed    


  4. KRUIS W, Siegmund B, Lesniakowski K, Simanenkov V, et al
    Novel Budesonide Suppository and Standard Budesonide Rectal Foam Induce High Rates of Clinical Remission and Mucosal Healing in Active Ulcerative Proctitis: a Randomised, Controlled, Non-inferiority Trial.
    J Crohns Colitis. 2022;16:1714-1724.
    PubMed     Abstract available


  5. ZUO L, Li J, Zhang X, Geng Z, et al
    Aberrant Mesenteric Adipose Extracellular Matrix Remodelling is Involved in Adipocyte Dysfunction in Crohn's Disease: The Role of TLR-4-mediated Macrophages.
    J Crohns Colitis. 2022;16:1762-1776.
    PubMed     Abstract available


  6. BACHOUR SP, Shah RS, Rieder F, Qazi T, et al
    Intra-abdominal septic complications after ileocolic resection increases risk for endoscopic and surgical postoperative Crohn's disease recurrence.
    J Crohns Colitis. 2022;16:1696-1705.
    PubMed     Abstract available


  7. BERERA S, Ioannou SC, Morillo D, Mantero AMA, et al
    Combining Pentoxifylline With Vedolizumab for Crohn's Disease: Results of a Randomised, Placebo-controlled Pilot Study.
    J Crohns Colitis. 2022;16:1687-1695.
    PubMed     Abstract available


  8. KORI M, Zamir Y, Yermiyahu SO, Ainbinder I, et al
    The association of Inflammatory Bowel Disease with Celiac Disease and Celiac Autoimmunity in children and adults: A nationwide study from the epi-IIRN.
    J Crohns Colitis. 2022 Nov 17. pii: 6832168. doi: 10.1093.
    PubMed     Abstract available


  9. KUMAR L, Doherty G
    The Tortoise (Endoscopy-Driven Treatment) and the Hare (Prophylactic Treatment): Who Wins the Race to Beat Post-Operative Recurrence of Crohn's Disease?
    J Crohns Colitis. 2022 Nov 17:jjac165. doi: 10.1093.
    PubMed    


  10. VAN DER DOES DE WILLEBOIS EML, Duijvestein M, Wasmann KA, D'Haens GRAM, et al
    Endoscopic Recurrence or Anastomotic Wound Healing Phenomenon after Ileocolic Resection for Crohn's Disease: The Challenges of Accurate Endoscopic Scoring.
    J Crohns Colitis. 2022 Nov 16:jjac175. doi: 10.1093.
    PubMed     Abstract available


  11. BATTAT R, Scherl EJ, Lukin D, Charilaou P, et al
    Increased Primary Bile Acids with Ileocolonic Resection Impact Ileal Inflammation and Gut Microbiota in Inflammatory Bowel Disease.
    J Crohns Colitis. 2022 Nov 2. pii: 6794155. doi: 10.1093.
    PubMed     Abstract available


  12. ELLUL P, Schembri J, Baldacchino VA, Molnar T, et al
    Post-inflammatory polyps burden as a prognostic marker of disease-outcome in patients with inflammatory bowel disease.
    J Crohns Colitis. 2022 Nov 2. pii: 6794125. doi: 10.1093.
    PubMed     Abstract available


  13. DUPONT-LUCAS C, Leroyer A, Ley D, Spyckerelle C, et al
    Increased risk of cancer and mortality in a large French population-based paediatric-onset inflammatory bowel disease retrospective cohort.
    J Crohns Colitis. 2022 Nov 1. pii: 6783208. doi: 10.1093.
    PubMed     Abstract available


  14. BOUCHER D, Barnich N
    Phage Therapy Against Adherent-invasive E. coli: Towards a Promising Treatment of Crohn's Disease Patients?
    J Crohns Colitis. 2022;16:1509-1510.
    PubMed    


  15. DAL BUONO A, Faita F, Peyrin-Biroulet L, Danese S, et al
    Ultrasound Elastography in Inflammatory Bowel Diseases: A Systematic Review of Accuracy Compared with Histopathological Assessment.
    J Crohns Colitis. 2022;16:1637-1646.
    PubMed     Abstract available


  16. DE VOOGD F, Bots S, Gecse K, Gilja OH, et al
    Intestinal Ultrasound Early on in Treatment Follow-up Predicts Endoscopic Response to Anti-TNFalpha Treatment in Crohn's Disease.
    J Crohns Colitis. 2022;16:1598-1608.
    PubMed     Abstract available


  17. DUBINSKY V, Reshef L, Rabinowitz K, Wasserberg N, et al
    Escherichia coli Strains from Patients with Inflammatory Bowel Diseases have Disease-specific Genomic Adaptations.
    J Crohns Colitis. 2022;16:1584-1597.
    PubMed     Abstract available


  18. MONFORT-FERRE D, Caro A, Menacho M, Marti M, et al
    The Gut Microbiota Metabolite Succinate Promotes Adipose Tissue Browning in Crohn's Disease.
    J Crohns Colitis. 2022;16:1571-1583.
    PubMed     Abstract available


  19. HU S, Mok J, Gowans M, Ong DEH, et al
    Oral Microbiome of Crohn's Disease Patients With and Without Oral Manifestations.
    J Crohns Colitis. 2022;16:1628-1636.
    PubMed     Abstract available


  20. KUMAR S, Parry T, Mallett S, Bhatnagar G, et al
    Diagnostic Performance of Magnetic Resonance Enterography Disease Activity Indices Compared with a Histological Reference Standard for Adult Terminal Ileal Crohn's Disease: Experience from the METRIC Trial.
    J Crohns Colitis. 2022;16:1531-1539.
    PubMed     Abstract available


    October 2022
  21. BARRAU M, Duprat M, Veyrard P, Tournier Q, et al
    A Systematic Review on the interest of Drug Tolerant assay in the monitoring of Inflammatory Bowel Disease.
    J Crohns Colitis. 2022 Oct 27. pii: 6775962. doi: 10.1093.
    PubMed     Abstract available


  22. LE HD, Pflaum T, Labrenz J, Sari S, et al
    Interobserver reliability of the Nancy index for ulcerative colitis: An assessment of the practicability and ease of use in a single-centre real-world setting.
    J Crohns Colitis. 2022 Oct 25. pii: 6773056. doi: 10.1093.
    PubMed     Abstract available


  23. TARGOWNIK L, Dubinsky MC, Steinwurz F, Bushmakin AG, et al
    Disease Activity and Health-related Quality of Life Relationships with Work Productivity in Patients with Ulcerative Colitis in OCTAVE Induction 1&2 and OCTAVE Sustain.
    J Crohns Colitis. 2022 Oct 22. pii: 6769962. doi: 10.1093.
    PubMed     Abstract available


  24. BYRNE MF, Panaccione R, East JE, Iacucci M, et al
    Application of Deep Learning Models to Improve Ulcerative Colitis Endoscopic Disease Activity Scoring Under Multiple Scoring Systems.
    J Crohns Colitis. 2022 Oct 18. pii: 6762568. doi: 10.1093.
    PubMed     Abstract available



  25. Erratum to: Prevalence and Outcomes of COVID-19 Among Patients With Inflammatory Bowel Disease-A Danish Prospective Population-based Cohort Study.
    J Crohns Colitis. 2022 Oct 17. pii: 6761987. doi: 10.1093.
    PubMed    


  26. FOLLIN-ARBELET B, Milada SC, Hovde O, Jelsness-Jorgensen LP, et al
    Mortality in patients with Inflammatory Bowel Disease: Results from 30 years of follow-up in a Norwegian inception cohort (the IBSEN study).
    J Crohns Colitis. 2022 Oct 14. pii: 6761119. doi: 10.1093.
    PubMed     Abstract available


  27. VIEUJEAN S, Moens A, Hassid D, Rothfuss K, et al
    Pneumocystis jirovecii pneumonia in patients with inflammatory bowel disease - A case series.
    J Crohns Colitis. 2022 Oct 12. pii: 6759599. doi: 10.1093.
    PubMed     Abstract available


  28. OTERO-PINEIRO AM, Jia X, Pedersen KE, Hull T, et al
    Surgical Intervention is Effective for the Treatment of Crohn's related Rectovaginal Fistulas: Experience From A Tertiary Inflammatory Bowel Disease Practice.
    J Crohns Colitis. 2022 Oct 11. pii: 6758392. doi: 10.1093.
    PubMed     Abstract available


  29. BAHNAM P, Hanzel J, Ma C, Zou L, et al
    Most placebo-controlled trials in inflammatory bowel disease were underpowered because of overestimated drug efficacy rates: Results from a systematic review of induction studies.
    J Crohns Colitis. 2022 Oct 11. pii: 6758390. doi: 10.1093.
    PubMed     Abstract available


  30. NYSTROM N, Prast-Nielsen S, Correia M, Globisch D, et al
    Mucosal and plasma metabolomes in new-onset paediatric inflammatory bowel disease: correlations with disease characteristics and plasma inflammation protein markers.
    J Crohns Colitis. 2022 Oct 11. pii: 6758389. doi: 10.1093.
    PubMed     Abstract available


  31. HANZEL J, Bossuyt P, Pittet V, Samaan M, et al
    Development of a Core Outcome Set for Real-World Data in Inflammatory Bowel Disease: A European Crohn's and Colitis Organisation (ECCO) Position Paper.
    J Crohns Colitis. 2022 Oct 3. pii: 6747109. doi: 10.1093.
    PubMed     Abstract available


    September 2022
  32. SCHOEFS E, Vermeire S, Ferrante M, Sabino J, et al
    What are the unmet needs and most relevant treatment outcomes according to patients with inflammatory bowel disease? A qualitative patient preference study.
    J Crohns Colitis. 2022 Sep 27. pii: 6722595. doi: 10.1093.
    PubMed     Abstract available


  33. CROFT NM, de Ridder L, Griffiths AM, Hyams JS, et al
    Paediatric inflammatory bowel disease: a multi-stakeholder perspective to improve development of drugs for children and adolescents.
    J Crohns Colitis. 2022 Sep 21. pii: 6710188. doi: 10.1093.
    PubMed     Abstract available


  34. LOUIS E, Siegel CA, James B, Heidenreich S, et al
    Patients with Inflammatory Bowel Disease Have Heterogeneous Treatment Preferences That Are Largely Determined by the Avoidance of Abdominal Pain and Side Effects [P-POWER IBD Study].
    J Crohns Colitis. 2022 Sep 20. pii: 6708291. doi: 10.1093.
    PubMed     Abstract available



  35. Erratum to: You Are What You Eat? Growing Evidence That Diet Influences the Risk of Inflammatory Bowel Disease.
    J Crohns Colitis. 2022 Sep 19. pii: 6706938. doi: 10.1093.
    PubMed    


  36. KURTI Z, Gonczi L, Lakatos L, Golovics P, et al
    Epidemiology, treatment strategy, natural disease course and surgical outcomes of patients with ulcerative colitis in Western Hungary - a population-based study between 2007 and 2018, data from the Veszprem County cohort.
    J Crohns Colitis. 2022 Sep 19. pii: 6705518. doi: 10.1093.
    PubMed     Abstract available


  37. DORN-RASMUSSEN M, Lo B, Zhao M, Kaplan GG, et al
    The incidence and prevalence of paediatric- and adult-onset inflammatory bowel disease in Denmark during a 37-year period - a nationwide cohort study (1980-2017).
    J Crohns Colitis. 2022 Sep 19. pii: 6705459. doi: 10.1093.
    PubMed     Abstract available


  38. WEWER MD, Langholz E, Munkholm P, Bendtsen F, et al
    Disease Activity Patterns of Inflammatory Bowel Disease - A Danish Nationwide Cohort Study 1995-2018.
    J Crohns Colitis. 2022 Sep 19. pii: 6705004. doi: 10.1093.
    PubMed     Abstract available


  39. SANDBORN WJ, D'Haens GR, Sands BE, Panaccione R, et al
    Tofacitinib for the treatment of ulcerative colitis: an integrated summary of up to 7.8 years of safety data from the global clinical program.
    J Crohns Colitis. 2022 Sep 17. pii: 6702643. doi: 10.1093.
    PubMed     Abstract available


  40. MORTLOCK S, Lord A, Montgomery G, Zakrzewski M, et al
    An extremes of phenotype approach confirms significant genetic heterogeneity in patients with ulcerative colitis.
    J Crohns Colitis. 2022 Sep 16. pii: 6701957. doi: 10.1093.
    PubMed     Abstract available


  41. OLIVERA PA, Lasa JS, Zubiaurre I, Jairath V, et al
    Opportunistic Infections in Patients with Inflammatory Bowel Disease Treated with Advanced Therapies: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    J Crohns Colitis. 2022 Sep 10. pii: 6695362. doi: 10.1093.
    PubMed     Abstract available


  42. DREWES AM
    Pain in Patients with Crohn's and Colitis: Can We Solve the Puzzle?
    J Crohns Colitis. 2022;16:1345-1346.
    PubMed    


  43. MAGRO F, Estevinho MM
    COVID-19 Vaccines in IBD Patients: Particularities and Future Perspectives.
    J Crohns Colitis. 2022;16:1343-1344.
    PubMed    


  44. SMITH PJ, Critchley L, Storey D, Gregg B, et al
    Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study.
    J Crohns Colitis. 2022;16:1436-1446.
    PubMed     Abstract available


  45. XU C, Jiang W, Wang L, Mao X, et al
    Intestinal Ultrasound for Differentiating Fibrotic or Inflammatory Stenosis in Crohn's Disease: A Systematic Review and Meta-analysis.
    J Crohns Colitis. 2022;16:1493-1504.
    PubMed     Abstract available


  46. BURRELLO C, Strati F, Lattanzi G, Diaz-Basabe A, et al
    IL10 Secretion Endows Intestinal Human iNKT Cells with Regulatory Functions Towards Pathogenic T Lymphocytes.
    J Crohns Colitis. 2022;16:1461-1474.
    PubMed     Abstract available


  47. SAVELKOUL EHJ, Maas MHJ, Bourgonje AR, Crouwel F, et al
    Favourable Tolerability and Drug Survival of Tioguanine Versus Methotrexate After Failure of Conventional Thiopurines in Crohn's Disease.
    J Crohns Colitis. 2022;16:1372-1379.
    PubMed     Abstract available


  48. SONNENBERG A, Genta RM
    Temporal changes in the histology of microscopic colitis.
    J Crohns Colitis. 2022;16:1415-1419.
    PubMed     Abstract available


  49. DOHERTY J, Morain NO, Stack R, Girod P, et al
    Reduced Serological Response to COVID-19 Vaccines in Patients with IBD is Further Diminished by TNF Inhibitor Therapy; Early Results of the VARIATION study [VAriability in Response in IBD Against SARS-COV-2 ImmunisatiON].
    J Crohns Colitis. 2022;16:1354-1362.
    PubMed     Abstract available


    August 2022
  50. VITALI R, Palone F, Armuzzi A, Fulci V, et al
    Proteomic analysis identifies three reliable biomarkers of intestinal inflammation in the stools of patients with Inflammatory Bowel Disease.
    J Crohns Colitis. 2022 Aug 30. pii: 6679173. doi: 10.1093.
    PubMed     Abstract available


  51. JULIEN C, Anakok E, Treton X, Nachury M, et al
    Impact of the Ileal Microbiota on Surgical Site Infections in Crohn's Disease: A Nationwide Prospective Cohort.
    J Crohns Colitis. 2022;16:1211-1221.
    PubMed     Abstract available


  52. BRETON J, Tanes C, Tu V, Albenberg L, et al
    A Microbial Signature for Paediatric Perianal Crohn's Disease.
    J Crohns Colitis. 2022;16:1281-1292.
    PubMed     Abstract available


  53. SUDHAKAR P, Alsoud D, Wellens J, Verstockt S, et al
    Tailoring Multi-omics to Inflammatory Bowel Diseases: All for One and One for All.
    J Crohns Colitis. 2022;16:1306-1320.
    PubMed     Abstract available


  54. NGOLLO M, Perez K, Hammoudi N, Gorelik Y, et al
    Identification of Gene Expression Profiles Associated with an Increased Risk of Post-Operative Recurrence in Crohn's Disease.
    J Crohns Colitis. 2022;16:1269-1280.
    PubMed     Abstract available


  55. KALLA R, Adams AT, Nowak JK, Bergemalm D, et al
    Analysis of systemic epigenetic alterations in inflammatory bowel disease: defining geographical, genetic, and immune-inflammatory influences on the circulating methylome.
    J Crohns Colitis. 2022 Aug 27. pii: 6677995. doi: 10.1093.
    PubMed     Abstract available


  56. LOFTUS EV, Vermeire S, Feagan BG, Le Brun FO, et al
    Corticosteroid-sparing Effects of Filgotinib in Moderate to Severely Active Ulcerative Colitis: Data from the Phase 2b/3 SELECTION Study.
    J Crohns Colitis. 2022 Aug 25. pii: 6675518. doi: 10.1093.
    PubMed     Abstract available


  57. NARULA N, Merat S, Liu D, Pugatch D, et al
    Time to endorse a sensitive method for scoring endoscopic activity of ulcerative colitis in clinical research.
    J Crohns Colitis. 2022 Aug 24. pii: 6674697. doi: 10.1093.
    PubMed     Abstract available


  58. JOUSTRA V, Hageman IL, Satsangi J, Adams A, et al
    Systematic Review and Meta-analysis of Peripheral Blood DNA methylation studies in Inflammatory Bowel Disease.
    J Crohns Colitis. 2022 Aug 23. pii: 6674036. doi: 10.1093.
    PubMed     Abstract available



  59. Corrigendum to: P169 Vitamin D levels are inversely associated with inflammation in pediatric Inflammatory Bowel Disease patients.
    J Crohns Colitis. 2022 Aug 22. pii: 6673037. doi: 10.1093.
    PubMed    


  60. LIN V, Gogenur S, Pachler F, Fransgaard T, et al
    Risk prediction for complications in Inflammatory Bowel Disease surgery: External validation of the American College of Surgeons' National Surgical Quality Improvement Program Surgical Risk Calculator.
    J Crohns Colitis. 2022 Aug 17. pii: 6668838. doi: 10.1093.
    PubMed     Abstract available


  61. HONAP S, Irving PM, Samaan MA
    Ustekinumab-Induced Inflammatory Demyelinating Polyneuropathy in a Patient with Ulcerative Colitis.
    J Crohns Colitis. 2022 Aug 12. pii: 6663939. doi: 10.1093.
    PubMed    


  62. CARON B, D'Amico F, Jairath V, Netter P, et al
    Available methods for benefit-risk assessment: lessons for inflammatory bowel disease drugs.
    J Crohns Colitis. 2022 Aug 11. pii: 6661406. doi: 10.1093.
    PubMed     Abstract available


  63. HARVEY PR, Coupland B, Mytton J, De Silva S, et al
    Venous thromboembolism following discharge from hospital in patients admitted for inflammatory bowel disease.
    J Crohns Colitis. 2022 Aug 10. pii: 6660709. doi: 10.1093.
    PubMed     Abstract available


  64. TORRES J, Gomes C, Jensen C, Agrawal M, et al
    Risk factors for developing Inflammatory Bowel Disease Within and Across Families with Family History of IBD.
    J Crohns Colitis. 2022 Aug 9. pii: 6659033. doi: 10.1093.
    PubMed     Abstract available


  65. LIU X, Ren X, Zhou L, Liu K, et al
    Tollip Orchestrates Macrophage Polarization to Alleviate Intestinal Mucosal Inflammation.
    J Crohns Colitis. 2022;16:1151-1167.
    PubMed     Abstract available


  66. NARULA N, Pray C, Wong ECL, Colombel JF, et al
    Categorising Endoscopic Severity of Crohn's Disease Using the Modified Multiplier SES-CD [MM-SES-CD].
    J Crohns Colitis. 2022;16:1011-1019.
    PubMed     Abstract available


  67. HUANG L, Qian W, Xu Y, Guo Z, et al
    Mesenteric Adipose Tissue Contributes to Intestinal Fibrosis in Crohn's Disease Through the ATX-LPA Axis.
    J Crohns Colitis. 2022;16:1124-1139.
    PubMed     Abstract available


  68. BARREIRO-DE ACOSTA M, Riestra S, Calafat M, Soto MP, et al
    Management and Long-term Outcomes of Crohn's Disease Complicated with Enterocutaneous Fistula: ECUFIT Study from GETECCU.
    J Crohns Colitis. 2022;16:1049-1058.
    PubMed     Abstract available


  69. FIERENS L, Liefferinckx C, Hoefkens E, Lobaton T, et al
    Introduction of Subcutaneous Infliximab CT-P13 and Vedolizumab in Clinical Practice: A Multi-Stakeholder Position Statement Highlighting the Need for Post-Marketing Studies.
    J Crohns Colitis. 2022;16:1059-1069.
    PubMed     Abstract available


  70. ABD EL AZIZ MA, Abdalla S, Calini G, Saeed H, et al
    Postoperative Safety Profile of Minimally Invasive Ileocolonic Resections for Crohn's Disease in the Era of Biologic Therapy.
    J Crohns Colitis. 2022;16:1079-1088.
    PubMed     Abstract available


  71. GAO H, He Q, Xu C, Pang Z, et al
    The Development and Validation of Anti-paratuberculosis-nocardia Polypeptide Antibody [Anti-pTNP] for the Diagnosis of Crohn's Disease.
    J Crohns Colitis. 2022;16:1110-1123.
    PubMed     Abstract available


  72. CROUWEL F, Buiter HJC, de Boer NK
    The Thiopurine Tale: An Unexpected Journey.
    J Crohns Colitis. 2022;16:1177-1183.
    PubMed     Abstract available


  73. DOUADI C, Vazeille E, Chambon C, Hebraud M, et al
    Anti-TNF Agents Restrict Adherent-invasive Escherichia coli Replication Within Macrophages Through Modulation of Chitinase 3-like 1 in Patients with Crohn's Disease.
    J Crohns Colitis. 2022;16:1140-1150.
    PubMed     Abstract available


  74. ATIA O, Kang B, Orlansky-Meyer E, Ledder O, et al
    Existing Prediction Models of Disease Course in Paediatric Crohn's Disease Are Poorly Replicated in a Prospective Inception Cohort.
    J Crohns Colitis. 2022;16:1039-1048.
    PubMed     Abstract available


    July 2022
  75. DIRVANSKYTE P, Gurram B, Bolton C, Warner N, et al
    Chromosomal numeric aberrations and rare copy number variation in patients with inflammatory bowel disease.
    J Crohns Colitis. 2022 Jul 30. pii: 6652479. doi: 10.1093.
    PubMed     Abstract available


  76. WONG D, Matini L, Kormilitzin A, Kantschuster R, et al
    Patient Reported Outcomes: the ICHOM Standard Set for inflammatory bowel disease in real life practice helps quantify deficits in current care.
    J Crohns Colitis. 2022 Jul 22. pii: 6648780. doi: 10.1093.
    PubMed     Abstract available


  77. YARUR AJ
    Intestinal Tissue Levels of Anti-Tumour Necrosis Factor Agents in Patients with Inflammatory Bowel Diseases: Are We Looking in The Right Place at The Right Time?
    J Crohns Colitis. 2022;16:869-870.
    PubMed    


  78. MAGRO F, Sabino J, Rosini F, Tripathi M, et al
    ECCO Position on Harmonisation of Crohn's Disease Mucosal Histopathology.
    J Crohns Colitis. 2022;16:876-883.
    PubMed     Abstract available


  79. SENSI B, Khan J, Warusavitarne J, Nardi A, et al
    Long-term Oncological Outcome of Segmental Versus Extended Colectomy for Colorectal Cancer in Crohn's Disease: Results from an International Multicentre Study.
    J Crohns Colitis. 2022;16:954-962.
    PubMed     Abstract available


  80. CHAKRABORTY R, Maltz MR, Del Castillo D, Tandel PN, et al
    Selective Targeting of Tumour Necrosis Factor Receptor 1 Induces Stable Protection from Crohn's-Like Ileitis in TNFDeltaARE Mice.
    J Crohns Colitis. 2022;16:978-991.
    PubMed     Abstract available


  81. PETERS V, Bolte L, Schuttert EM, Andreu-Sanchez S, et al
    Western and Carnivorous Dietary Patterns are Associated with Greater Likelihood of IBD Development in a Large Prospective Population-based Cohort.
    J Crohns Colitis. 2022;16:931-939.
    PubMed     Abstract available


  82. CARON B, Sandborn WJ, Panaccione R, Schreiber S, et al
    Efficacy of Pharmacological Agents for Ulcerative Proctitis: A Systematic Literature Review.
    J Crohns Colitis. 2022;16:922-930.
    PubMed     Abstract available


  83. WALSHE M, Nayeri S, Ji J, Hernandez-Rocha C, et al
    A Role for CXCR3 Ligands as Biomarkers of Post-Operative Crohn's Disease Recurrence.
    J Crohns Colitis. 2022;16:900-910.
    PubMed     Abstract available


  84. SWAMINATHAN A, Borichevsky GM, Edwards TS, Hirschfeld E, et al
    Faecal Myeloperoxidase as a Biomarker of Endoscopic Activity in Inflammatory Bowel Disease.
    J Crohns Colitis. 2022 Jul 8. pii: 6634254. doi: 10.1093.
    PubMed     Abstract available


    June 2022
  85. ZHANG R, Lauwers GY, Choi WT
    Increased Risk of Non-Conventional and Invisible Dysplasias in Patients with Primary Sclerosing Cholangitis and Inflammatory Bowel Disease.
    J Crohns Colitis. 2022 Jun 30. pii: 6623587. doi: 10.1093.
    PubMed     Abstract available



  86. Corrigendum to: ECCO CONFER Investigators, Diagnosis and Outcome of Extranodal Primary Intestinal Lymphoma in Inflammatory Bowel Disease: An ECCO CONFER Case Series.
    J Crohns Colitis. 2022 Jun 25. pii: 6617788. doi: 10.1093.
    PubMed    


  87. HONAP S, Meade S, Spencer A, Pavlidis P, et al
    Anogenital Crohn's Disease and Granulomatosis: A Systematic Review of Epidemiology, Clinical Manifestations, and Treatment.
    J Crohns Colitis. 2022;16:822-834.
    PubMed     Abstract available


  88. VIGORITA V, Cano-Valderrama O, Celentano V, Vinci D, et al
    Inflammatory Bowel Diseases Benefit from Enhanced Recovery After Surgery [ERAS] Protocol: A Systematic Review with Practical Implications.
    J Crohns Colitis. 2022;16:845-851.
    PubMed     Abstract available


  89. ATIA O, Harel S, Ledderman N, Greenfeld S, et al
    Risk of Cancer in Paediatric onset Inflammatory Bowel Diseases: A Nation-wide Study From the epi-IIRN.
    J Crohns Colitis. 2022;16:786-795.
    PubMed     Abstract available


  90. ATIA O, Orlanski-Meyer E, Lujan R, Ledderman N, et al
    Improved Outcomes of Paediatric and Adult Crohn's Disease and Association With Emerging Use of Biologics-A Nationwide Study From the Epi-IIRN.
    J Crohns Colitis. 2022;16:778-785.
    PubMed     Abstract available


  91. ALMRADI A, Sedano R, Hogan M, Zou GY, et al
    Clinical, Endoscopic, and Safety Placebo Rates in Induction and Maintenance Trials of Crohn's Disease: Meta-Analysis of Randomised Controlled Trials.
    J Crohns Colitis. 2022;16:717-736.
    PubMed     Abstract available


  92. D'HAENS G, Danese S, Davies M, Watanabe M, et al
    A phase II, Multicentre, Randomised, Double-Blind, Placebo-controlled Study to Evaluate Safety, Tolerability, and Efficacy of Amiselimod in Patients with Moderate to Severe Active Crohn's Disease.
    J Crohns Colitis. 2022;16:746-756.
    PubMed     Abstract available


  93. ATTAUABI M, Dahlerup JF, Poulsen A, Hansen MR, et al
    Outcomes and Long-Term Effects of COVID-19 in Patients with Inflammatory Bowel Diseases - A Danish Prospective Population-Based Cohort Study with Individual-Level Data.
    J Crohns Colitis. 2022;16:757-767.
    PubMed     Abstract available


  94. VAN RIJN KL, Meima-van Praag EM, Bossuyt PM, D'Haens GR, et al
    Fibrosis and MAGNIFI-CD Activity Index at Magnetic Resonance Imaging to Predict Treatment Outcome in Perianal Fistulizing Crohn's Disease Patients.
    J Crohns Colitis. 2022;16:708-716.
    PubMed     Abstract available


  95. REENAERS C, Louis E
    Progressing Towards the Implementation of a Treat-To-Target Strategy in Perianal Crohn's Disease.
    J Crohns Colitis. 2022;16:693-694.
    PubMed    


  96. ILVEMARK JFKF, Wilkens R, Thielsen P, Dige A, et al
    Early intestinal ultrasound predicts intravenous corticosteroid response in hospitalized patients with severe ulcerative colitis.
    J Crohns Colitis. 2022 Jun 13. pii: 6607631. doi: 10.1093.
    PubMed     Abstract available


  97. KIM KO, Kim EY, Lee YJ, Lee HS, et al
    Efficacy, safety and tolerability of oral sulfate tablet for bowel preparation in patients with inflammatory bowel disease: Multicenter randomized controlled study.
    J Crohns Colitis. 2022 Jun 11. pii: 6605993. doi: 10.1093.
    PubMed     Abstract available


  98. JAGT JZ, Verburgt CM, de Vries R, de Boer NKH, et al
    Faecal metabolomics in paediatric inflammatory bowel disease: a systematic review.
    J Crohns Colitis. 2022 Jun 9. pii: 6605030. doi: 10.1093.
    PubMed     Abstract available


  99. CLARKSTON K, Karns R, Jegga AG, Sharma M, et al
    Targeted Assessment of Mucosal Immune Gene Expression Predicts Clinical Outcomes in Children with Ulcerative Colitis.
    J Crohns Colitis. 2022 Jun 4. pii: 6602063. doi: 10.1093.
    PubMed     Abstract available


    May 2022
  100. TORRENTE F, Meade S, Benchimol EI, de Ridder L, et al
    Thromboprophylaxis use in paediatric inflammatory bowel disease: an international RAND appropriateness panel.
    J Crohns Colitis. 2022 May 24. pii: 6591364. doi: 10.1093.
    PubMed     Abstract available


  101. DANESE S, Peyrin-Biroulet L
    Evolution of IL-23 Blockade in Inflammatory Bowel Disease.
    J Crohns Colitis. 2022;16.
    PubMed    


  102. SEWELL GW, Kaser A
    Interleukin-23 in the Pathogenesis of Inflammatory Bowel Disease and Implications for Therapeutic Intervention.
    J Crohns Colitis. 2022;16.
    PubMed     Abstract available


  103. PARIGI TL, Iacucci M, Ghosh S
    Blockade of IL-23: What is in the Pipeline?
    J Crohns Colitis. 2022;16.
    PubMed     Abstract available


  104. D'AMICO F, Peyrin-Biroulet L, Danese S
    Ustekinumab in Crohn's Disease: New Data for Positioning in Treatment Algorithm.
    J Crohns Colitis. 2022;16.
    PubMed     Abstract available


  105. MCDONALD BD, Dyer EC, Rubin DT
    IL-23 Monoclonal Antibodies for IBD: So Many, So Different?
    J Crohns Colitis. 2022;16.
    PubMed     Abstract available


  106. VALENTI M, Narcisi A, Pavia G, Gargiulo L, et al
    What Can IBD Specialists Learn from IL-23 Trials in Dermatology?
    J Crohns Colitis. 2022;16.
    PubMed     Abstract available


  107. ATREYA R, Neurath MF
    IL-23 Blockade in Anti-TNF Refractory IBD: From Mechanisms to Clinical Reality.
    J Crohns Colitis. 2022;16.
    PubMed     Abstract available


  108. GOTTLIEB ZS, Sands BE
    Personalised Medicine with IL-23 Blockers: Myth or Reality?
    J Crohns Colitis. 2022;16.
    PubMed     Abstract available


  109. CALVET X, Panes J, Gallardo-Escudero J, de la Cuadra-Grande A, et al
    Multicriteria Decision Analysis for Updating of Quality Indicators for Inflammatory Bowel Disease Comprehensive Care Units in Spain.
    J Crohns Colitis. 2022 May 11. pii: 6584605. doi: 10.1093.
    PubMed     Abstract available


  110. ROGLER G
    No Need to Scope? Monitoring of Treatment Response in IBD Patients by Transabdominal Ultrasound.
    J Crohns Colitis. 2022;16:521-522.
    PubMed    


  111. KAKUTA Y, Iwaki H, Umeno J, Kawai Y, et al
    Crohn's Disease and Early Exposure to Thiopurines are Independent Risk Factors for Mosaic Chromosomal Alterations in Patients with Inflammatory Bowel Diseases.
    J Crohns Colitis. 2022;16:643-655.
    PubMed     Abstract available


  112. VERBURGT CM, Dunn KA, Van Limbergen JE
    Dietary Therapy Reduces Pro-inflammatory Microbiome Features in Paediatric Crohn's Disease.
    J Crohns Colitis. 2022;16:682-684.
    PubMed    


  113. NARULA N, Wong ECL, Colombel JF, Sandborn WJ, et al
    Early Reduction in MM-SES-CD Score After Initiation of Biologic Therapy is Highly Specific for 1-year Endoscopic Remission in Moderate to Severe Crohn's Disease.
    J Crohns Colitis. 2022;16:616-624.
    PubMed     Abstract available


  114. BOTS S, De Voogd F, De Jong M, Ligtvoet V, et al
    Point-of-care Intestinal Ultrasound in IBD Patients: Disease Management and Diagnostic Yield in a Real-world Cohort and Proposal of a Point-of-care Algorithm.
    J Crohns Colitis. 2022;16:606-615.
    PubMed     Abstract available


  115. DAOUD ND, Hashash JG, Picco MF, Farraye FA, et al
    Faecal Calprotectin from Ileostomy Output Is Sensitive and Specific for the Prediction of Small Bowel Inflammation in Patients with Crohn's Disease.
    J Crohns Colitis. 2022;16:601-605.
    PubMed     Abstract available


  116. KUCHARZIK T, Tielbeek J, Carter D, Taylor SA, et al
    ECCO-ESGAR Topical Review on Optimizing Reporting for Cross-Sectional Imaging in Inflammatory Bowel Disease.
    J Crohns Colitis. 2022;16:523-543.
    PubMed     Abstract available


  117. SUN TY, Li YQ, Zhao FQ, Sun HM, et al
    MiR-1-3p and MiR-124-3p Synergistically Damage the Intestinal Barrier in the Ageing Colon.
    J Crohns Colitis. 2022;16:656-667.
    PubMed     Abstract available


  118. ALSOUD D, De Hertogh G, Compernolle G, Tops S, et al
    Real-world endoscopic and histologic outcomes are correlated with ustekinumab exposure in patients with ulcerative colitis.
    J Crohns Colitis. 2022 May 9. pii: 6582859. doi: 10.1093.
    PubMed     Abstract available


  119. STODTMANN S, Chen MJ, Siovitz L, Bereswill M, et al
    Bridging Fixed Dose to Body Weight-Based Regimen of Adalimumab in Pediatric Ulcerative Colitis Using a Pharmacometric Modeling Approach: Case Study with the Phase 3 ENVISION I Trial.
    J Crohns Colitis. 2022 May 8. pii: 6582407. doi: 10.1093.
    PubMed     Abstract available


  120. SHRESTHA S, Brand JS, Jaras J, Schoultz I, et al
    Association between inflammatory bowel disease and spondyloarthritis: findings from a nationwide study in Sweden.
    J Crohns Colitis. 2022 May 5. pii: 6581445. doi: 10.1093.
    PubMed     Abstract available


  121. WONG C, van Oostrom J, Bossuyt P, Pittet V, et al
    A narrative systematic review and categorisation of outcomes in Inflammatory Bowel Disease to inform a Core Outcome Set for real-world evidence.
    J Crohns Colitis. 2022 May 5. pii: 6580715. doi: 10.1093.
    PubMed     Abstract available


  122. POULLENOT F, Amiot A, Nachury M, Viennot S, et al
    Comparative risk of incident cancer in patients with Inflammatory Bowel Disease with prior non-digestive malignancy according to immunomodulator: a multicenter cohort study.
    J Crohns Colitis. 2022 May 5. pii: 6580681. doi: 10.1093.
    PubMed     Abstract available


    April 2022
  123. DE GALAN C, Truyens M, Peeters H, Mesonero Gismero F, et al
    The impact of vedolizumab and ustekinumab on articular extra-intestinal manifestations in inflammatory bowel disease patients: a real-life multicentric cohort study.
    J Crohns Colitis. 2022 Apr 20. pii: 6571450. doi: 10.1093.
    PubMed     Abstract available


  124. FERNANDEZ ME, Nazar FN, Moine LB, Jaime CE, et al
    Network analysis of inflammatory bowel disease research: towards the interactome.
    J Crohns Colitis. 2022 Apr 19. pii: 6570854. doi: 10.1093.
    PubMed     Abstract available


  125. UNGARO RC, Chou B, Mo J, Ursos L, et al
    Impact of COVID-19 on Healthcare Resource Utilization among Patients with Inflammatory Bowel Disease in the USA.
    J Crohns Colitis. 2022 Apr 9. pii: 6565722. doi: 10.1093.
    PubMed     Abstract available


  126. DONG C, Chan SSM, Jantchou P, Racine A, et al
    Meat intake is associated with a higher risk of ulcerative colitis in a large European prospective cohort study.
    J Crohns Colitis. 2022 Apr 9. pii: 6565743. doi: 10.1093.
    PubMed     Abstract available


  127. DOLINGER MT, Rolfes P, Spencer E, Stoffels G, et al
    Outcomes of Children With Inflammatory Bowel Disease Who Develop Anti-Tumor Necrosis Factor Induced Skin Reactions.
    J Crohns Colitis. 2022 Apr 7. pii: 6564796. doi: 10.1093.
    PubMed     Abstract available


  128. HARDY PY, Fikri J, Libbrecht D, Louis E, et al
    Pain characteristics in patients with inflammatory bowel disease: A monocentric cross-sectional study.
    J Crohns Colitis. 2022 Apr 4. pii: 6563361. doi: 10.1093.
    PubMed     Abstract available


  129. CHAPARRO M, Kunovsky L, Aguas M, Livne M, et al
    Surgery Due to Inflammatory Bowel Disease During Pregnancy: Mothers and Offspring Outcomes From an Ecco Confer Multicentre Case Series (Scar Study).
    J Crohns Colitis. 2022 Apr 4. pii: 6563346. doi: 10.1093.
    PubMed     Abstract available


  130. COLLEN LV, Kim DY, Field M, Okoroafor I, et al
    Clinical Phenotypes and Outcomes in Monogenic versus Non-Monogenic Very Early Onset Inflammatory Bowel Disease.
    J Crohns Colitis. 2022 Apr 2. pii: 6562761. doi: 10.1093.
    PubMed     Abstract available


    March 2022
  131. CERNA K, Duricova D, Hindos M, Hindos HJ, et al
    Cellular and humoral immune responses to SARS-CoV-2 vaccination in inflammatory bowel disease patients.
    J Crohns Colitis. 2022 Mar 31. pii: 6561818. doi: 10.1093.
    PubMed     Abstract available


  132. KHAN N, Trivedi C, Aberra F, Pernes T, et al
    Safety of Recombinant Zoster Vaccine in Patients with Inflammatory Bowel Disease.
    J Crohns Colitis. 2022 Mar 29. pii: 6555677. doi: 10.1093.
    PubMed     Abstract available


  133. DING NS, Tassone D, Al-Bakir I, Wu K, et al
    Systematic review: The impact and importance of body composition in Inflammatory Bowel Disease.
    J Crohns Colitis. 2022 Mar 24. pii: 6553364. doi: 10.1093.
    PubMed     Abstract available


  134. MORTENSEN JH, Sinkeviciute D, Manon-Jensen T, Domislovic V, et al
    A specific calprotectin neo-epitope (CPa9-HNE) in serum from inflammatory bowel disease patients is associated with neutrophil activity and endoscopic severity.
    J Crohns Colitis. 2022 Mar 19. pii: 6550845. doi: 10.1093.
    PubMed     Abstract available


  135. HYAMS JS, Turner D, Cohen SA, Szakos E, et al
    Pharmacokinetics, Safety, and Efficacy of Intravenous Vedolizumab in Paediatric Patients with Ulcerative Colitis or Crohn's Disease: Results from the Phase 2 HUBBLE Study.
    J Crohns Colitis. 2022 Mar 17. pii: 6550285. doi: 10.1093.
    PubMed     Abstract available


  136. VELOSA M, Hochner H, Yerushalmi B, Harel S, et al
    Pre and perinatal factors predicting Inflammatory Bowel Disease - a population-based study with fifty years follow-up.
    J Crohns Colitis. 2022 Mar 17. pii: 6550290. doi: 10.1093.
    PubMed     Abstract available


  137. SANDBORN WJ, Lewis JD, Panes J, Loftus EV, et al
    Association Between Proposed Definitions of Clinical Remission/Response and Well-Being in Patients With Crohn's Disease.
    J Crohns Colitis. 2022;16:444-451.
    PubMed     Abstract available


  138. SUAU R, Pardina E, Domenech E, Loren V, et al
    The Complex Relationship Between Microbiota, Immune Response and Creeping Fat in Crohn's Disease.
    J Crohns Colitis. 2022;16:472-489.
    PubMed     Abstract available


  139. BLE A, Renzulli C, Cenci F, Grimaldi M, et al
    The Relationship Between Endoscopic and Clinical Recurrence in Postoperative Crohn's Disease: A Systematic Review and Meta-analysis.
    J Crohns Colitis. 2022;16:490-499.
    PubMed     Abstract available


  140. PHILLIPS F, Verstockt B, Sladek M, de Boer N, et al
    Orofacial Granulomatosis Associated with Crohn's Disease: a Multicentre Case Series.
    J Crohns Colitis. 2022;16:430-435.
    PubMed     Abstract available


  141. NGUYEN NH, Picetti D, Dulai PS, Jairath V, et al
    Machine Learning-based Prediction Models for Diagnosis and Prognosis in Inflammatory Bowel Diseases: A Systematic Review.
    J Crohns Colitis. 2022;16:398-413.
    PubMed     Abstract available


  142. VIEUJEAN S, Loly JP, Boutaffala L, Meunier P, et al
    Mesenchymal Stem Cell Injection in Crohn's Disease Strictures: A Phase I-II Clinical Study.
    J Crohns Colitis. 2022;16:506-510.
    PubMed     Abstract available


  143. CHANCHLANI N, Lin S, Chee D, Hamilton B, et al
    Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses: Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated Patients.
    J Crohns Colitis. 2022;16:389-397.
    PubMed     Abstract available


  144. LEVER G, Chipeta H, Glanville T, Selinger C, et al
    Perineal Outcomes After Delivery in 179 Mothers with Inflammatory Bowel Disease Compared to 31 258 Controls: A Single-Centre Cohort Study.
    J Crohns Colitis. 2022;16:511-514.
    PubMed     Abstract available


  145. FEAKINS R, Torres J, Borralho-Nunes P, Burisch J, et al
    ECCO Topical Review on Clinicopathological Spectrum and Differential Diagnosis of Inflammatory Bowel Disease.
    J Crohns Colitis. 2022;16:343-368.
    PubMed     Abstract available


  146. ROBERTSON AR, Webster KL
    Disease activity in the final years of life for patients with longstanding Inflammatory Bowel Disease.
    J Crohns Colitis. 2022 Mar 7. pii: 6543872. doi: 10.1093.
    PubMed    


  147. ABREU MT, Rowbotham DS, Danese S, Sandborn WJ, et al
    Efficacy and Safety of Maintenance Ustekinumab for Ulcerative Colitis Through 3 Years: UNIFI Long-term Extension.
    J Crohns Colitis. 2022 Mar 3. pii: 6542054. doi: 10.1093.
    PubMed     Abstract available


  148. SCIBERRAS M, Karmiris K, Nascimento C, Tabone T, et al
    Mental health, work presenteeism and exercise in inflammatory bowel disease.
    J Crohns Colitis. 2022 Mar 3. pii: 6542057. doi: 10.1093.
    PubMed     Abstract available


  149. BURGESS CJ, Schnier C, Wood R, Henderson P, et al
    Prematurity, delivery method and infant feeding type are not associated with paediatric-onset inflammatory bowel disease risk: A Scottish retrospective birth cohort study.
    J Crohns Colitis. 2022 Mar 1. pii: 6540489. doi: 10.1093.
    PubMed     Abstract available


    February 2022
  150. COTTRON C, Treton X, Altwegg R, Reenaers C, et al
    How to manage inflammatory bowel disease patients when they withdraw anti-TNF due to severe anti-TNF-induced skin lesions? A multicenter cohort study.
    J Crohns Colitis. 2022 Feb 26. pii: 6537448. doi: 10.1093.
    PubMed     Abstract available


  151. NOWAK JK, Adams AT, Kalla R, Lindstrom JC, et al
    Characterization of the circulating transcriptomic landscape in inflammatory bowel disease provides evidence for dysregulation of multiple transcription factors including NFE2, SPI1, CEBPB, and IRF2.
    J Crohns Colitis. 2022 Feb 25. pii: 6536718. doi: 10.1093.
    PubMed     Abstract available


  152. TRACY M, Khalili H
    You Are What You Eat? Growing Evidence That Diet Influences the Risk of Inflammatory Bowel Disease.
    J Crohns Colitis. 2022 Feb 23. pii: 6534662. doi: 10.1093.
    PubMed    


  153. BISLENGHI G, Sucameli F, Fieuws S, Ferrante M, et al
    Non-conventional Versus Conventional Strictureplasties for Crohn's Disease. A Systematic Review and Meta-analysis of Treatment Outcomes.
    J Crohns Colitis. 2022;16:319-330.
    PubMed     Abstract available


  154. DHALIWAL J, Carroll MW, deBruyn JC, Ricciuto A, et al
    The Phenotypic Spectrum of New-onset IBD in Canadian Children of South Asian Ethnicity: A Prospective Multi-Centre Comparative Study.
    J Crohns Colitis. 2022;16:216-223.
    PubMed     Abstract available


  155. CLEMENT F, Nougarede A, Combe S, Kermarrec F, et al
    Therapeutic siRNAs Targeting the JAK/STAT Signalling Pathway in Inflammatory Bowel Diseases.
    J Crohns Colitis. 2022;16:286-300.
    PubMed     Abstract available


  156. ELDRIDGE F, Raine T
    Understanding and Addressing the Psychological Burden of IBD.
    J Crohns Colitis. 2022;16:177-178.
    PubMed    


  157. LAUDISI F, Stolfi C, Bevivino G, Maresca C, et al
    GATA6 Deficiency Leads to Epithelial Barrier Dysfunction and Enhances Susceptibility to Gut Inflammation.
    J Crohns Colitis. 2022;16:301-311.
    PubMed     Abstract available


  158. BACSUR P, Farkas K, Molnar T
    Area of the IBD Disk Correlated Strongly with Disease Activity Compared with the Conventionally Used IBD Disk Score.
    J Crohns Colitis. 2022;16:336.
    PubMed    


  159. OSTROWSKI S, Croft A
    Viral enteric infections in acute severe ulcerative colitis.
    J Crohns Colitis. 2022 Feb 15. pii: 6528523. doi: 10.1093.
    PubMed     Abstract available


  160. CROFT A, Lord A, Radford-Smith G
    Markers of systemic inflammation in acute attacks of ulcerative colitis: What level of C-reactive protein constitutes severe colitis?
    J Crohns Colitis. 2022 Feb 11. pii: 6527048. doi: 10.1093.
    PubMed     Abstract available


  161. MOOKHOEK A, Haasnoot ML, Bredenoord AJ, Ma C, et al
    The clinical significance of eosinophils in ulcerative colitis: a systematic review.
    J Crohns Colitis. 2022 Feb 9. pii: 6524727. doi: 10.1093.
    PubMed     Abstract available


  162. HUA X, Lopes EW, Burke KE, Ananthakrishnan AN, et al
    Smoking behavior changes after diagnosis of inflammatory bowel disease and risk of all-cause mortality.
    J Crohns Colitis. 2022 Feb 1. pii: 6518234. doi: 10.1093.
    PubMed     Abstract available


    January 2022
  163. VERMEIRE S, D'Haens G, Baert F, Danese S, et al
    Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the VISIBLE 2 Randomised Trial.
    J Crohns Colitis. 2022;16:27-38.
    PubMed     Abstract available


  164. ALBSHESH A, Eder P, Ribaldone DG, Oldenburg B, et al
    Primary Hypogammaglobulinaemia with Inflammatory Bowel Disease-Like Features: An ECCO CONFER Multicentre Case Series.
    J Crohns Colitis. 2022;16:91-97.
    PubMed     Abstract available


  165. ZILBAUER M, Heuschkel R
    Disease Prognostic Biomarkers in Inflammatory Bowel Diseases-A Reality Check.
    J Crohns Colitis. 2022;16:162-165.
    PubMed     Abstract available


  166. FERREIRA JPS, de Mascarenhas Saraiva MJDQEC, Afonso JPL, Ribeiro TFC, et al
    Identification of Ulcers and Erosions by the Novel Pillcam Crohn's Capsule Using a Convolutional Neural Network: A Multicentre Pilot Study.
    J Crohns Colitis. 2022;16:169-172.
    PubMed     Abstract available


  167. HELWIG U, Fischer I, Hammer L, Kolterer S, et al
    Transmural Response and Transmural Healing Defined by Intestinal Ultrasound: New Potential Therapeutic Targets?
    J Crohns Colitis. 2022;16:57-67.
    PubMed     Abstract available


  168. KABIR M, Thomas-Gibson S, Hart AL, Wilson A, et al
    Perception of Cancer Risk and Management Practice for Colitis-associated Dysplasia Is Influenced by Colonoscopy Experience and Workplace Affiliation: Results of an International Clinician Survey.
    J Crohns Colitis. 2022;16:39-48.
    PubMed     Abstract available


  169. FULFORTH J, Gearry R
    Inequitable Access to IBD Therapies Extends Beyond Developing Nations.
    J Crohns Colitis. 2022;16:173-174.
    PubMed    


  170. HANZEL J, Jairath V
    A TIGER Among Endoscopic Indices in Inflammatory Bowel Disease.
    J Crohns Colitis. 2022 Jan 21. pii: 6513472. doi: 10.1093.
    PubMed    


  171. NUNEZ F P, Quera R, Bay C, Castro F, et al
    Drug-induced liver injury used in the treatment of Inflammatory Bowel Disease.
    J Crohns Colitis. 2022 Jan 19. pii: 6511546. doi: 10.1093.
    PubMed     Abstract available


  172. ELLUL P, Reves J, Abreu B, Chaparro M, et al
    Implementation and short-term adverse events of anti-SARS-CoV-2 vaccines in Inflammatory Bowel Disease patients: an international web-based survey.
    J Crohns Colitis. 2022 Jan 17. pii: 6509060. doi: 10.1093.
    PubMed     Abstract available


  173. JUZENAS S, Hubenthal M, Lindqvist CM, Kruse R, et al
    Detailed transcriptional landscape of peripheral blood points to increased neutrophil activation in treatment-naive inflammatory bowel disease.
    J Crohns Colitis. 2022 Jan 11. pii: 6503823. doi: 10.1093.
    PubMed     Abstract available


  174. DE BOER NK, van Lookeren FL, Tack GJ
    The launch of an online national multidisciplinary expert panel for inflammatory bowel disease.
    J Crohns Colitis. 2022 Jan 6. pii: 6499222. doi: 10.1093.
    PubMed    


  175. HERNANDEZ-ROCHA C, Nayeri S, Turpin W, Steel M, et al
    Combined histo-endoscopic remission but not endoscopic healing alone in ulcerative colitis is associated with a mucosal transcriptional profile resembling healthy mucosa.
    J Crohns Colitis. 2022 Jan 6. pii: 6499459. doi: 10.1093.
    PubMed     Abstract available


  176. TORRENTE F, Hansen R
    Venous Thromboembolism in Children with Inflammatory Bowel Disease: When is the Right Time for Thromboprophylaxis?
    J Crohns Colitis. 2022 Jan 3. pii: 6494523. doi: 10.1093.
    PubMed    


    December 2021
  177. VENTRESS E, Young D, Rahmany S, Harris C, et al
    Transitioning from intRavenous to subcutAneous VEdolizumab in patients with infLammatory bowEl diSeaSe (TRAVELESS).
    J Crohns Colitis. 2021 Dec 22. pii: 6478741. doi: 10.1093.
    PubMed     Abstract available


  178. GIANNINI EG, Demarzo MG, Bodini G
    Elevated Adherence to Vaccination Against SARS-CoV-2 Among Patients with Inflammatory Bowel Disease.
    J Crohns Colitis. 2021;15:2142-2143.
    PubMed    


  179. GOLDBERG R, Clough JN, Roberts LB, Sanchez J, et al
    A Crohn's Disease-associated IL2RA Enhancer Variant Determines the Balance of T Cell Immunity by Regulating Responsiveness to IL-2 Signalling.
    J Crohns Colitis. 2021;15:2054-2065.
    PubMed     Abstract available


  180. RYVCHIN R, Dubinsky V, Rabinowitz K, Wasserberg N, et al
    Alteration in Urease-producing Bacteria in the Gut Microbiomes of Patients with Inflammatory Bowel Diseases.
    J Crohns Colitis. 2021;15:2066-2077.
    PubMed     Abstract available


  181. SPALINGER MR, Schwarzfischer M, Niechcial A, Atrott K, et al
    Loss of PTPN22 Promotes Intestinal Inflammation by Compromising Granulocyte-mediated Antibacterial Defence.
    J Crohns Colitis. 2021;15:2118-2130.
    PubMed     Abstract available


  182. DERIKX LAAP, Dolby HW, Plevris N, Lucaciu L, et al
    Effectiveness and Safety of Adalimumab Biosimilar SB5 in Inflammatory Bowel Disease: Outcomes in Originator to SB5 Switch, Double Biosimilar Switch and Bio-Naive SB5 Observational Cohorts.
    J Crohns Colitis. 2021;15:2011-2021.
    PubMed     Abstract available


  183. FERRANTE M, Feagan BG, Panes J, Baert F, et al
    Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn's Disease: Results from the Phase 2 Open-Label Extension Study.
    J Crohns Colitis. 2021;15:2001-2010.
    PubMed     Abstract available


  184. NI H, Chen Y, Xia W, Wang C, et al
    SATB2 Defect Promotes Colitis and Colitis-associated Colorectal Cancer by Impairing Cl-/HCO3- Exchange and Homeostasis of Gut Microbiota.
    J Crohns Colitis. 2021;15:2088-2102.
    PubMed     Abstract available


  185. WANG L, Zhang N, Han D, Su P, et al
    MTDH Promotes Intestinal Inflammation by Positively Regulating TLR Signalling.
    J Crohns Colitis. 2021;15:2103-2117.
    PubMed     Abstract available


  186. CASADO-BEDMAR M, Viennois E
    microRNA and gut microbiota: Tiny but mighty - Novel insights of their crosstalk in inflammatory bowel disease pathogenesis and therapeutics.
    J Crohns Colitis. 2021 Dec 16. pii: 6464304. doi: 10.1093.
    PubMed     Abstract available


  187. CALAFAT M, Manosa M, Ricart E, Nos P, et al
    Risk of immunomediated adverse events and loss of response to infliximab in elderly patients with inflammatory bowel disease. A cohort study of the ENEIDA registry.
    J Crohns Colitis. 2021 Dec 3. pii: 6448705. doi: 10.1093.
    PubMed     Abstract available


  188. FESTA S, Zerboni G, Derikx LAAP, Ribaldone DG, et al
    Gastroenteropancreatic Neuroendocrine Neoplasms in Patients with Inflammatory Bowel Disease: An ECCO CONFER Multicentre Case Series.
    J Crohns Colitis. 2021 Dec 1. pii: 6447455. doi: 10.1093.
    PubMed     Abstract available


    November 2021
  189. GORDON IO, Abushamma S, Kurowski JA, Holubar SD, et al
    Pediatric Ulcerative Colitis Is A Fibrotic Disease And Linked With Chronicity Of Inflammation.
    J Crohns Colitis. 2021 Nov 29. pii: 6445941. doi: 10.1093.
    PubMed     Abstract available


  190. BAR-YOSEPH H, Blatt A, Gerassy S, Pressman S, et al
    Differential serum-intestinal dynamics of infliximab and adalimumab in inflammatory bowel disease patients.
    J Crohns Colitis. 2021 Nov 24. pii: 6438514. doi: 10.1093.
    PubMed     Abstract available


  191. PRENTICE RE, Ross AL, Flanagan EK
    Management of Pregnant Women with Inflammatory Bowel Disease and COVID-19-Balancing Risks of Delayed Treatment Recommencement.
    J Crohns Colitis. 2021 Nov 23. pii: 6433604. doi: 10.1093.
    PubMed    


  192. PAPAEFTHYMIOU A, Potamianos S, Goulas A, Doulberis M, et al
    Inflammatory Bowel Disease-associated Fatty Liver Disease: the Potential Effect of Biologic Agents.
    J Crohns Colitis. 2021 Nov 22. pii: 6433262. doi: 10.1093.
    PubMed     Abstract available


  193. ATIA O, Orlanski-Meyer E, Lujan R, Ledderman N, et al
    Colectomy Rates did not Decrease in Paediatric- and Adult-Onset Ulcerative Colitis During the Biologics Era: A Nationwide Study From the epi-IIRN.
    J Crohns Colitis. 2021 Nov 20. pii: 6432553. doi: 10.1093.
    PubMed     Abstract available


  194. BACSUR P, Farkas K, Molnar T
    Outcome of immediate dose optimization of infliximab in inflammatory bowel disease patients.
    J Crohns Colitis. 2021 Nov 18. pii: 6430840. doi: 10.1093.
    PubMed    


  195. GUPTA R, MacIsaac M, Wright EK
    Sleeve gastrectomy in patients with inflammatory bowel disease is not associated with worsening disease.
    J Crohns Colitis. 2021 Nov 17. pii: 6430439. doi: 10.1093.
    PubMed    


  196. D'AMICO F, Magro F, Peyrin-Biroulet L, Danese S, et al
    Positioning filgotinib in the treatment algorithm of moderate to severe ulcerative colitis.
    J Crohns Colitis. 2021 Nov 16. pii: 6429427. doi: 10.1093.
    PubMed     Abstract available


  197. NICHOLSON MR, Alexander E, Ballal S, Davidovics Z, et al
    Efficacy and Outcomes of Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection in Children with Inflammatory Bowel Disease.
    J Crohns Colitis. 2021 Nov 12. pii: 6425925. doi: 10.1093.
    PubMed     Abstract available


  198. VAN ERP LW, Neijenhuis MK, Heida W, Derwig J, et al
    Improving care for recently diagnosed inflammatory bowel disease patients: Lessons learned from a patient-centred, mixed-method study.
    J Crohns Colitis. 2021 Nov 10. pii: 6425110. doi: 10.1093.
    PubMed     Abstract available


  199. CHARPY F, Altwegg R, Debourdeau A
    Disseminated tuberculosis in a patient treated with tofacitinib for ulcerative colitis.
    J Crohns Colitis. 2021 Nov 9. pii: 6424411. doi: 10.1093.
    PubMed    


  200. AGRAWAL M, Zhang X, Brenner EJ, Ungaro RC, et al
    The Impact of Vedolizumab on COVID-19 Outcomes Among Adult IBD Patients in the SECURE-IBD Registry.
    J Crohns Colitis. 2021;15:1877-1884.
    PubMed     Abstract available


  201. WETWITTAYAKHLANG P, Lakatos PL
    Comforting Data on the Incidence of Rectal Cancer After Subtotal Colectomy in IBD: The Risk Is Low, Yet Surveillance Matters!
    J Crohns Colitis. 2021;15:1783-1784.
    PubMed    


  202. ROSH JR, Turner D, Griffiths A, Cohen SA, et al
    Ustekinumab in Paediatric Patients with Moderately to Severely Active Crohn's Disease: Pharmacokinetics, Safety, and Efficacy Results from UniStar, a Phase 1 Study.
    J Crohns Colitis. 2021;15:1931-1942.
    PubMed     Abstract available


  203. REZAZADEH ARDABILI A, Goudkade D, Wintjens D, Romberg-Camps M, et al
    Histopathological Features in Colonic Biopsies at Diagnosis Predict Long-term Disease Course in Patients with Crohn's Disease.
    J Crohns Colitis. 2021;15:1885-1897.
    PubMed     Abstract available


  204. SELIN KA, Hedin CRH, Villablanca EJ
    Immunological Networks Defining the Heterogeneity of Inflammatory Bowel Diseases.
    J Crohns Colitis. 2021;15:1959-1973.
    PubMed     Abstract available


  205. NAFTALI T, Bar-Lev Schleider L, Almog S, Meiri D, et al
    Oral CBD-rich Cannabis Induces Clinical but Not Endoscopic Response in Patients with Crohn's Disease, a Randomised Controlled Trial.
    J Crohns Colitis. 2021;15:1799-1806.
    PubMed     Abstract available


  206. LUO J, Xu Z, Noordam R, van Heemst D, et al
    Depression and Inflammatory Bowel Disease: A Bidirectional two-sample Mendelian Randomization Study.
    J Crohns Colitis. 2021 Nov 5. pii: 6421452. doi: 10.1093.
    PubMed     Abstract available


    October 2021
  207. GARRIDO I, Lopes S, Macedo G
    "Safety of COVID-19 vaccination in inflammatory bowel disease patients on biologic therapy".
    J Crohns Colitis. 2021 Oct 30. pii: 6414658. doi: 10.1093.
    PubMed    


  208. LIMA SF, Longman RS
    Eating for Two: Diet and the Microbiome in Ulcerative Colitis.
    J Crohns Colitis. 2021 Oct 27. pii: 6412629. doi: 10.1093.
    PubMed    


  209. FRIEDMAN S, Zegers FD, Jolving LR, Nielsen J, et al
    Postpartum surgical complications in women with inflammatory bowel disease after caesarian section: A Danish nationwide cohort study.
    J Crohns Colitis. 2021 Oct 27. pii: 6412778. doi: 10.1093.
    PubMed     Abstract available


  210. CHARKAOUI M, Hajage D, Tubach F, Laurent B, et al
    Impact of anti-tumor necrosis factor agents on the risk of colorectal cancer in patients with ulcerative colitis: nationwide French cohort study.
    J Crohns Colitis. 2021 Oct 18. pii: 6399096. doi: 10.1093.
    PubMed     Abstract available


  211. RAINE T, Bonovas S, Burisch J, Kucharzik T, et al
    ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment.
    J Crohns Colitis. 2021 Oct 12. pii: 6390052. doi: 10.1093.
    PubMed    


  212. SPINELLI A, Bonovas S, Burisch J, Kucharzik T, et al
    ECCO Guidelines on Therapeutics in Ulcerative Colitis: Surgical Treatment.
    J Crohns Colitis. 2021 Oct 12. pii: 6390023. doi: 10.1093.
    PubMed     Abstract available


  213. ELFIKY AMI, Ghiboub M, Li Yim AYF, Hageman IL, et al
    Carboxylesterase-1 assisted targeting of HDAC inhibitors to mononuclear myeloid cells in Inflammatory Bowel Disease.
    J Crohns Colitis. 2021 Oct 11. pii: 6387695. doi: 10.1093.
    PubMed     Abstract available


  214. WALENTYNOWICZ M, van de Pavert I, Fierens L, Coenen S, et al
    Inflammatory Bowel Disease-related Behaviours [IBD-Bx] questionnaire: Development, validation, and prospective associations with fatigue.
    J Crohns Colitis. 2021 Oct 8. pii: 6383644. doi: 10.1093.
    PubMed     Abstract available


  215. JOJART B, Molnar T, Szabo V, Varga A, et al
    Erratum to: P459 Expression of SerpinE1, a potential new disease activity marker, reflects therapeutic response in Inflammatory Bowel Disease.
    J Crohns Colitis. 2021 Oct 7. pii: 6383122. doi: 10.1093.
    PubMed    


  216. ADAMINA M, Fiorino G
    At the Crossroads of Caution and Intervention: Anti-TNF Therapy Prior to Elective CD Surgery.
    J Crohns Colitis. 2021;15:1778-1779.
    PubMed    


  217. MEKORI-DOMACHEVSKY E, Ben-Horin S
    Holistic approach to IBD patients.
    J Crohns Colitis. 2021;15:1782.
    PubMed    


  218. SOOP M, Hancock L, Davies J
    Anti-TNF Therapy Before Intestinal Surgery for Crohn's Disease and the Risks of Postoperative Complications.
    J Crohns Colitis. 2021;15:1777.
    PubMed    


  219. HONAP S, Irving PM, Kennedy NA
    Response to 'Clinical Efficacy of Tofacitinib in Moderate to Severe Ulcerative Colitis'.
    J Crohns Colitis. 2021;15:1775-1776.
    PubMed    


  220. RAINE T, Verstockt B, Kopylov U, Karmiris K, et al
    ECCO Topical Review: Refractory Inflammatory Bowel Disease.
    J Crohns Colitis. 2021;15:1605-1620.
    PubMed     Abstract available


  221. UNGAR B, Malickova K, Hanzel J, Abu Arisha M, et al
    Dose optimisation for Loss of Response to Vedolizumab- Pharmacokinetics and Immune Mechanisms.
    J Crohns Colitis. 2021;15:1707-1719.
    PubMed     Abstract available


  222. VIEUJEAN S, Hu S, Bequet E, Salee C, et al
    Potential Role of Epithelial Endoplasmic Reticulum Stress and Anterior Gradient Protein 2 Homologue in Crohn's Disease Fibrosis.
    J Crohns Colitis. 2021;15:1737-1750.
    PubMed     Abstract available


  223. NARULA N, Wong ECL, Dulai PS, Marshall JK, et al
    Outcomes of Passable and Non-passable Strictures in Clinical Trials of Crohn's Disease: A Post-hoc Analysis.
    J Crohns Colitis. 2021;15:1649-1657.
    PubMed     Abstract available


  224. ILVEMARK JFKF, Hansen T, Goodsall TM, Seidelin JB, et al
    Defining transabdominal Intestinal Ultrasound treatment response and remission in Inflammatory Bowel Disease: Systematic review and expert consensus statement.
    J Crohns Colitis. 2021 Oct 6. pii: 6382324. doi: 10.1093.
    PubMed     Abstract available


  225. AARDOOM MA, Klomberg RCW, Kemos P, Ruemmele FM, et al
    The incidence and characteristics of venous thromboembolisms in paediatric-onset inflammatory bowel disease; a prospective international cohort study based on the PIBD-SETQuality Safety Registry.
    J Crohns Colitis. 2021 Oct 2. pii: 6380289. doi: 10.1093.
    PubMed     Abstract available


    September 2021
  226. RICCIUTO A, Lamb CA, Benchimol EI, Walker GJ, et al
    Inflammatory Bowel Disease Clinical Activity Is Associated with COVID-19 Severity Especially in Younger Patients.
    J Crohns Colitis. 2021 Sep 27. pii: 6376474. doi: 10.1093.
    PubMed     Abstract available


  227. DART RJ, Ellul P, Scharl M, Lamb CA, et al
    Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBD - Challenges and Future Directions.
    J Crohns Colitis. 2021;15:1407-1409.
    PubMed    


  228. FIOCCHI C, Dragoni G, Iliopoulos D, Katsanos K, et al
    Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBD-What, Why, and How.
    J Crohns Colitis. 2021;15:1410-1430.
    PubMed     Abstract available


  229. VERSTOCKT B, Noor NM, Marigorta UM, Pavlidis P, et al
    Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBD-Disease Outcome and Response to Therapy.
    J Crohns Colitis. 2021;15:1431-1442.
    PubMed     Abstract available


  230. LI Y, Zhu L, Chen P, Wang Y, et al
    MALAT1 Maintains the Intestinal Mucosal Homeostasis in Crohn's Disease via the miR-146b-5p-CLDN11/NUMB Pathway.
    J Crohns Colitis. 2021;15:1542-1557.
    PubMed     Abstract available


  231. DE KRIJGER M, Wildenberg ME, Mookhoek A, Verheul S, et al
    Expression of MAdCAM-1 and Gut-homing T Cells in Inflamed Pouch Mucosa.
    J Crohns Colitis. 2021;15:1491-1499.
    PubMed     Abstract available


  232. RUSSO E, Giudici F, Ricci F, Scaringi S, et al
    Diving into Inflammation: A Pilot Study Exploring the Dynamics of the Immune-Microbiota Axis in Ileal Tissue Layers of Patients with Crohn's Disease.
    J Crohns Colitis. 2021;15:1500-1516.
    PubMed     Abstract available


  233. SOLA TAPIAS N, Denadai-Souza A, Rolland-Fourcade C, Quaranta-Nicaise M, et al
    Colitis Linked to Endoplasmic Reticulum Stress Induces Trypsin Activity Affecting Epithelial Functions.
    J Crohns Colitis. 2021;15:1528-1541.
    PubMed     Abstract available


  234. CHEN D, Fulmer C, Gordon IO, Syed S, et al
    Application of Artificial Intelligence to Clinical Practice in Inflammatory Bowel Disease - What the Clinician Needs to Know.
    J Crohns Colitis. 2021 Sep 24. pii: 6374854. doi: 10.1093.
    PubMed     Abstract available


  235. WONG D, Travis SPL
    Patient-reported Goals in Inflammatory Bowel Disease: What's the Problem?
    J Crohns Colitis. 2021 Sep 21. pii: 6373333. doi: 10.1093.
    PubMed    


  236. SARBAGILI SHABAT C, Scaldaferri F, Zittan E, Hirsch A, et al
    Use of Fecal transplantation with a novel diet for mild to moderate active ulcerative colitis: The CRAFT UC randomized controlled trial.
    J Crohns Colitis. 2021 Sep 13. pii: 6369227. doi: 10.1093.
    PubMed     Abstract available


  237. PHILLIPS F, Verstockt B, Ribaldone DG, Guerra I, et al
    Diagnosis and outcome of extranodal primary intestinal lymphoma in inflammatory bowel disease: an ECCO CONFER case series.
    J Crohns Colitis. 2021 Sep 11. pii: 6368841. doi: 10.1093.
    PubMed     Abstract available


  238. KIM GH, Lee YC, Kim TJ, Kim ER, et al
    Risk of neurodegenerative diseases in patients with inflammatory bowel disease: a nationwide population-based cohort study.
    J Crohns Colitis. 2021 Sep 9. pii: 6367800. doi: 10.1093.
    PubMed     Abstract available


  239. BOURGONJE AR, Hu S, Spekhorst LM, Zhernakova DV, et al
    The Effect of Phenotype and Genotype on the Plasma Proteome in Patients with Inflammatory Bowel Disease.
    J Crohns Colitis. 2021 Sep 7. pii: 6365883. doi: 10.1093.
    PubMed     Abstract available


    August 2021
  240. BOTS S, Nylund K, Gecse K
    Response to letter to the editor "Intestinal Ultrasound to Assess Disease Activity in Ulcerative Colitis: Development of a novel UC-Ultrasound index".
    J Crohns Colitis. 2021 Aug 14. pii: 6352305. doi: 10.1093.
    PubMed    


  241. CARON B, D'Amico F, Danese S, Peyrin-Biroulet L, et al
    Cluster Randomized Trials: Lessons for Inflammatory Bowel Disease Trials.
    J Crohns Colitis. 2021 Aug 14. pii: 6352195. doi: 10.1093.
    PubMed     Abstract available


  242. REUKEN PA, Andreas N, Grunert PC, Glockner S, et al
    T cell response after SARS-CoV-2 vaccination in immunocompromised patients with inflammatory bowel disease.
    J Crohns Colitis. 2021 Aug 11. pii: 6348138. doi: 10.1093.
    PubMed     Abstract available


  243. CROWLEY E, Ma C, Andic M, Feagan BG, et al
    Impact of Drug Approval Pathways for Paediatric Inflammatory Bowel Disease.
    J Crohns Colitis. 2021 Aug 11. pii: 6348023. doi: 10.1093.
    PubMed     Abstract available


  244. TSE CS, Van Citters AD, Ricci B, Freundlich NZ, et al
    Identifying and Predicting the Goals and Concerns Prioritized by Individuals with Inflammatory Bowel Disease.
    J Crohns Colitis. 2021 Aug 5. pii: 6341120. doi: 10.1093.
    PubMed     Abstract available


  245. CARVELLO M, Bellato V, Maroli A, Hart A, et al
    A multidisciplinary approach to rectal cancer treatment in ulcerative colitis results in high rate of restorative minimally invasive surgery.
    J Crohns Colitis. 2021 Aug 4. pii: 6338719. doi: 10.1093.
    PubMed     Abstract available


  246. PROIETTI E, Fuhler GM, Peppelenbosch MP
    Mycobacterium Avium Subspecies Paratuberculosis Infection and Biological Treatment of IBD: Cause or Consequence?
    J Crohns Colitis. 2021;15:1247-1249.
    PubMed    


  247. WELLENS J, Colombel JF, Satsangi JJ, Wong SY, et al
    SARS-CoV-2 Vaccination in IBD: Past Lessons, Current Evidence, and Future Challenges.
    J Crohns Colitis. 2021;15:1376-1386.
    PubMed     Abstract available


  248. LOCHHEAD P, Khalili H, Sachs MC, Chan AT, et al
    Statin Use and Risk of Inflammatory Bowel Diseases: Authors' Reply.
    J Crohns Colitis. 2021;15:1403-1404.
    PubMed    


  249. TURSI A, Mocci G, Maconi G
    Effect of Ustekinumab on Extraintestinal Diseases in Refractory Crohn's Disease.
    J Crohns Colitis. 2021;15:1399-1400.
    PubMed    


  250. CARON B, D'Amico F, Danese S, Peyrin-Biroulet L, et al
    Endpoints for Perianal Crohn's Disease Trials: Past, Present and Future.
    J Crohns Colitis. 2021;15:1387-1398.
    PubMed     Abstract available


  251. ELLRICHMANN M, Bethge J, Boesenkoetter J, Conrad C, et al
    Subclinical Pulmonary Involvement in Active IBD Responds to Biologic Therapy.
    J Crohns Colitis. 2021;15:1339-1345.
    PubMed     Abstract available


  252. CAER C, Gorreja F, Forsskahl SK, Brynjolfsson SF, et al
    TREM-1+ Macrophages Define a Pathogenic Cell Subset in the Intestine of Crohn's Disease Patients.
    J Crohns Colitis. 2021;15:1346-1361.
    PubMed     Abstract available


  253. CAMBI MPC, Yamamoto T, Kotze PG
    Importance of Nutrition and Hypoalbuminaemia in Postoperative Morbidity in Crohn's Disease: Thinking Outside of the Box on Biologics as Single Risk Factors.
    J Crohns Colitis. 2021;15:1401-1402.
    PubMed    


  254. CHANG I, Park S, Lee HJ, Kim I, et al
    Interpretation of XIAP Variants of Uncertain Significance in Paediatric Patients with Refractory Crohn's Disease.
    J Crohns Colitis. 2021;15:1291-1304.
    PubMed     Abstract available


  255. PETERS V, Spooren CEGM, Pierik MJ, Weersma RK, et al
    Dietary Intake Pattern is Associated with Occurrence of Flares in IBD Patients.
    J Crohns Colitis. 2021;15:1305-1315.
    PubMed     Abstract available


    July 2021
  256. SEDANO R, Hogan M, Nguyen TM, Chang J, et al
    Systematic review and Meta-analysis: Clinical, Endoscopic, Histologic and Safety Placebo Rates in Induction and Maintenance trials of Ulcerative Colitis.
    J Crohns Colitis. 2021 Jul 26. pii: 6328606. doi: 10.1093.
    PubMed     Abstract available


  257. PARK SH, Im JP, Park H, Jeong SK, et al
    Clinical features and long-term outcomes of pediatric-onset inflammatory bowel disease in a population-based cohort in the Songpa-Kangdong district of Seoul, Korea.
    J Crohns Colitis. 2021 Jul 26. pii: 6328476. doi: 10.1093.
    PubMed     Abstract available


  258. BOSSUYT P, Pouillon L, Claeys S, D'Haens S, et al
    Ultra-proactive therapeutic drug monitoring of infliximab based on point-of-care-testing in inflammatory bowel disease: results of a pragmatic trial.
    J Crohns Colitis. 2021 Jul 23. pii: 6326544. doi: 10.1093.
    PubMed     Abstract available


  259. CHEE D, Nice R, Hamilton B, Jones E, et al
    Patient-led Remote IntraCapillary pharmacoKinetic Sampling (fingerPRICKS) for therapeutic drug monitoring in patients with inflammatory bowel disease.
    J Crohns Colitis. 2021 Jul 21. pii: 6325142. doi: 10.1093.
    PubMed     Abstract available


  260. DIEZ-OBRERO V, Moratalla-Navarro F, Ibanez-Sanz G, Guardiola J, et al
    Transcriptome-wide association study for inflammatory bowel disease reveals novel candidate susceptibility genes in specific colon subsites and tissue categories.
    J Crohns Colitis. 2021 Jul 21. pii: 6324884. doi: 10.1093.
    PubMed     Abstract available


  261. ZITTAN E, Steinhart AH, Aran H, Milgrom R, et al
    The Toronto Ibd Global Endoscopic Reporting (Tiger) Score: A Single, Easy To Use Endoscopic Score For Both Crohn's Disease And Ulcerative Colitis Patients.
    J Crohns Colitis. 2021 Jul 17. pii: 6323260. doi: 10.1093.
    PubMed     Abstract available


  262. DINALLO V, Di Fusco D, Di Grazia A, Laudisi F, et al
    The deubiquitinating enzyme OTUD5 sustains inflammatory cytokine response in inflammatory bowel disease.
    J Crohns Colitis. 2021 Jul 7. pii: 6316763. doi: 10.1093.
    PubMed     Abstract available


  263. CHOI WT, Salomao M, Zhao L, Alpert L, et al
    Hypermucinous, Goblet Cell Deficient, and Crypt Cell Dysplasias in Inflammatory Bowel Disease are Often Associated with Flat/Invisible Endoscopic Appearance and Advanced Neoplasia on Follow-Up.
    J Crohns Colitis. 2021 Jul 7. pii: 6316756. doi: 10.1093.
    PubMed     Abstract available


  264. DELISLE M, Wilkens R, Novak KL
    Keeping It Simple: Using Intestinal Ultrasound to Assess Ulcerative Colitis with a Novel UC-Ultrasound Index.
    J Crohns Colitis. 2021 Jul 5. pii: 6315708. doi: 10.1093.
    PubMed    


  265. RESTELLINI S, Lakatos PL
    Patient-Reported Outcomes in Inflammatory Bowel Diseases: Another Piece in the Puzzle.
    J Crohns Colitis. 2021;15:1085-1086.
    PubMed    


  266. GUPTA V, Mohsen W, Chapman TP, Satsangi J, et al
    Predicting Outcome in Acute Severe Colitis-Controversies in Clinical Practice in 2021.
    J Crohns Colitis. 2021;15:1211-1221.
    PubMed     Abstract available


  267. DAI C, Jiang M, Huang YH
    Association Between Statin Use and Inflammatory Bowel Diseases.
    J Crohns Colitis. 2021;15:1246.
    PubMed    


  268. ADAMINA M, Feakins R, Iacucci M, Spinelli A, et al
    ECCO Topical Review Optimising Reporting in Surgery, Endoscopy, and Histopathology.
    J Crohns Colitis. 2021;15:1089-1105.
    PubMed     Abstract available


  269. XU M, Shen Y, Cen M, Zhu Y, et al
    Modulation of the Gut Microbiota-farnesoid X Receptor Axis Improves Deoxycholic Acid-induced Intestinal Inflammation in Mice.
    J Crohns Colitis. 2021;15:1197-1210.
    PubMed     Abstract available


  270. LI XH, Feng ST, Cao QH, Coffey JC, et al
    Degree of Creeping Fat Assessed by Computed Tomography Enterography is Associated with Intestinal Fibrotic Stricture in Patients with Crohn's Disease: A Potentially Novel Mesenteric Creeping Fat Index.
    J Crohns Colitis. 2021;15:1161-1173.
    PubMed     Abstract available


  271. KIM PH, Kim SH, Cho YA, Yoon HM, et al
    Ability of Pelvic Magnetic Resonance Imaging to Predict Clinical Course of Perianal Fistula in Paediatric Crohn's Disease Patients.
    J Crohns Colitis. 2021;15:1152-1160.
    PubMed     Abstract available


  272. SHAH RS, Bachour S, Jia X, Holubar SD, et al
    Hypoalbuminaemia, Not Biologic Exposure, Is Associated with Postoperative Complications in Crohn's Disease Patients Undergoing Ileocolic Resection.
    J Crohns Colitis. 2021;15:1142-1151.
    PubMed     Abstract available


  273. POLETTI M, Arnauts K, Ferrante M, Korcsmaros T, et al
    Organoid-based Models to Study the Role of Host-microbiota Interactions in IBD.
    J Crohns Colitis. 2021;15:1222-1235.
    PubMed     Abstract available


  274. WONG ECL, Buffone E, Lee SJ, Dulai PS, et al
    End of Induction Patient-reported Outcomes Predict Clinical Remission but Not Endoscopic Remission in Crohn's Disease.
    J Crohns Colitis. 2021;15:1114-1119.
    PubMed     Abstract available


  275. COX SR, Clarke H, O'Keeffe M, Dubois P, et al
    Nutrient, fibre and FODMAP intakes and food-related quality of life in patients with inflammatory bowel disease and their relationship with gastrointestinal symptoms of differing aetiologies.
    J Crohns Colitis. 2021 Jul 3. pii: 6314229. doi: 10.1093.
    PubMed     Abstract available


    June 2021
  276. WATANABE S, Hibiya S, Katsukura N, Kitagawa S, et al
    Importance of telomere shortening in the pathogenesis of ulcerative colitis: A new treatment from the aspect of telomeres in intestinal epithelial cells.
    J Crohns Colitis. 2021 Jun 28. pii: 6310549. doi: 10.1093.
    PubMed     Abstract available


  277. GUBATAN J, Rubin SJS, Bai L, Haileselassie Y, et al
    Vitamin D is Associated with alpha4beta7+ Immunophenotypes and Predicts Vedolizumab Therapy Failure in Patients with Inflammatory Bowel Disease.
    J Crohns Colitis. 2021 Jun 28. pii: 6310486. doi: 10.1093.
    PubMed     Abstract available


  278. KUENZIG ME, Bitton A, Carroll MW, Kaplan GG, et al
    Inflammatory bowel disease increases the risk of venous thromboembolism in children: a population-based matched cohort study.
    J Crohns Colitis. 2021 Jun 27. pii: 6310166. doi: 10.1093.
    PubMed     Abstract available


  279. KIM PH, Yoon HM, Jung AY, Lee JS, et al
    Diagnostic Performance of Diffusion-weighted Imaging for Evaluation of Bowel Inflammation in Pediatric Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.
    J Crohns Colitis. 2021 Jun 22. pii: 6308099. doi: 10.1093.
    PubMed     Abstract available


  280. GILMORE R, Hilley P, Srinivasan A, Choy M, et al
    Sequential use of high-dose tofacitinib after infliximab salvage therapy in acute severe ulcerative colitis.
    J Crohns Colitis. 2021 Jun 22. pii: 6308093. doi: 10.1093.
    PubMed     Abstract available


  281. ABAKKOUY Y, Cleynen I
    The Promise of Polygenic Risk Scores as a Research Tool to Analyse the Genetics Underlying IBD Phenotypes.
    J Crohns Colitis. 2021;15:877-878.
    PubMed    


  282. ATTAUABI M, Seidelin JB, Burisch J
    Authors' Reply to: 'COVID-19 in the IBD Population: The Need for Correct Nomenclature'.
    J Crohns Colitis. 2021;15:1080.
    PubMed    


  283. STOCKER D, King MJ, El Homsi M, Carbonell G, et al
    Luminal Narrowing Alone Allows an Accurate Diagnosis of Crohn's Disease Small Bowel Strictures at Cross-Sectional Imaging.
    J Crohns Colitis. 2021;15:1009-1018.
    PubMed     Abstract available


  284. BUISSON A, Filippi J, Amiot A, Cadiot G, et al
    Defining and Assessing the Reproducibility of Crohn's Disease Endoscopic Lesions: A Delphi-like Method from the GETAID.
    J Crohns Colitis. 2021;15:1000-1008.
    PubMed     Abstract available


  285. SYAL G, Shemtov R, Bonthala N, Vasiliauskas EA, et al
    Pre-pouch Ileitis is Associated with Development of Crohn's Disease-like Complications and Pouch Failure.
    J Crohns Colitis. 2021;15:960-968.
    PubMed     Abstract available


  286. GIANOTTI RJ, Cheifetz AS
    Cannabis and Inflammatory Bowel Disease: All Smoke and Mirrors?
    J Crohns Colitis. 2021 Jun 17. pii: 6301791. doi: 10.1093.
    PubMed    


  287. JOHNSON AM, Harmsen WS, Aniwan S, Tremaine WJ, et al
    Prevalence and Impact of Obesity on Disease-Specific Outcomes in a Population-Based Cohort of Patients with Ulcerative Colitis.
    J Crohns Colitis. 2021 Jun 12. pii: 6297429. doi: 10.1093.
    PubMed     Abstract available


  288. PORTER RJ, Arends MJ, Churchhouse AMD, Din S, et al
    Inflammatory bowel disease-associated colorectal cancer: translational risks from mechanisms to medicines.
    J Crohns Colitis. 2021 Jun 10. pii: 6295922. doi: 10.1093.
    PubMed     Abstract available


  289. GHOSH S, Sanchez Gonzalez Y, Zhou W, Clark R, et al
    Upadacitinib Treatment Improves Symptoms of Bowel Urgency and Abdominal Pain, and Correlates With Quality of Life Improvements in Patients With Moderate to Severe Ulcerative Colitis.
    J Crohns Colitis. 2021 Jun 9. pii: 6295522. doi: 10.1093.
    PubMed     Abstract available


  290. HERNANDEZ-ROCHA C, Borowski K, Turpin W, Filice M, et al
    Integrative analysis of colonic biopsies from inflammatory bowel disease patients identifies an interaction between microbial bile-acid inducible gene abundance and human Angiopoietin-like 4 gene expression.
    J Crohns Colitis. 2021 Jun 2. pii: 6291049. doi: 10.1093.
    PubMed     Abstract available


    May 2021
  291. FUMERY M, Chatelain D
    Histological Scores in Inflammatory Bowel Disease: A New Kid in the Block.
    J Crohns Colitis. 2021 May 27. pii: 6286012. doi: 10.1093.
    PubMed    


  292. DHERI AK, Kuenzig ME, Mack DR, Murthy SK, et al
    Shifting health care use from hospitalizations and surgeries to outpatient visits in children with inflammatory bowel disease: a population-based cohort study from Ontario, Canada.
    J Crohns Colitis. 2021 May 21. pii: 6279878. doi: 10.1093.
    PubMed     Abstract available


  293. WEISSMAN S, Patel K, Kolli S, Lipcsey M, et al
    Obesity in Inflammatory Bowel Disease is Associated with Early Readmissions characterized by an Increased Systems and Patient-level Burden.
    J Crohns Colitis. 2021 May 17. pii: 6276891. doi: 10.1093.
    PubMed     Abstract available


  294. REZAZADEH ARDABILI A, Creemers RH, van Bodegraven AA
    COVID-19 in the IBD Population: The Need for Correct Nomenclature.
    J Crohns Colitis. 2021;15:872-873.
    PubMed    


  295. BERTE' R, Mazza S, Stefanucci MR, Noviello D, et al
    Seroprevalence of SARS-CoV2 in IBD Patients Treated with Biologic Therapy.
    J Crohns Colitis. 2021;15:864-868.
    PubMed     Abstract available


  296. REZAZADEH ARDABILI A, Hendrix EMB, Pierik MJ
    Remote Monitoring of Inflammatory Bowel Disease: What Kind of Patient-Reported Questionnaires Should We Use?
    J Crohns Colitis. 2021;15:869-870.
    PubMed    


  297. CROSBY S, Schuh MJ, Farraye FA
    Rechallenge with Subcutaneous Ustekinumab After Hypersensitivity Reaction to Intravenous Ustekinumab.
    J Crohns Colitis. 2021;15:871.
    PubMed    


  298. ASHTON JJ, Boukas K, Davies J, Stafford IS, et al
    Ileal Transcriptomic Analysis in Paediatric Crohn's Disease Reveals IL17- and NOD-signalling Expression Signatures in Treatment-naive Patients and Identifies Epithelial Cells Driving Differentially Expressed Genes.
    J Crohns Colitis. 2021;15:774-786.
    PubMed     Abstract available


  299. LOCHHEAD P, Khalili H, Sachs MC, Chan AT, et al
    Association Between Statin Use and Inflammatory Bowel Diseases: Results from a Swedish, Nationwide, Population-based Case-control Study.
    J Crohns Colitis. 2021;15:757-765.
    PubMed     Abstract available


  300. KLANG E, Grinman A, Soffer S, Margalit Yehuda R, et al
    Automated Detection of Crohn's Disease Intestinal Strictures on Capsule Endoscopy Images Using Deep Neural Networks.
    J Crohns Colitis. 2021;15:749-756.
    PubMed     Abstract available


  301. MOTTA JP, Palese S, Giorgio C, Chapman K, et al
    Increased Mucosal Thrombin is Associated with Crohn's Disease and Causes Inflammatory Damage through Protease-activated Receptors Activation.
    J Crohns Colitis. 2021;15:787-799.
    PubMed     Abstract available


  302. NELSON A, Stewart CJ, Kennedy NA, Lodge JK, et al
    The Impact of NOD2 Genetic Variants on the Gut Mycobiota in Crohn's Disease Patients in Remission and in Individuals Without Gastrointestinal Inflammation.
    J Crohns Colitis. 2021;15:800-812.
    PubMed     Abstract available


  303. MULLER M, D'Amico F, Bonovas S, Danese S, et al
    TNF Inhibitors and Risk of Malignancy in Patients with Inflammatory Bowel Diseases: A Systematic Review.
    J Crohns Colitis. 2021;15:840-859.
    PubMed     Abstract available


    April 2021
  304. VAN ERP LW, van Gerven J, Bloem S, Groenen MJM, et al
    Acceptance and perceived control are independently associated with quality of life in inflammatory bowel disease: Introduction of a new segmentation model.
    J Crohns Colitis. 2021 Apr 28. pii: 6257076. doi: 10.1093.
    PubMed     Abstract available


  305. STRAATMIJER T, Biemans VBC, Hoentjen F, de Boer NKH, et al
    Ustekinumab for Crohn's Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, a Nationwide Prospective Observational Cohort Study.
    J Crohns Colitis. 2021 Apr 28. pii: 6256992. doi: 10.1093.
    PubMed     Abstract available


  306. OUAHED J, Kelsen JR, Spessott WA, Kooshesh K, et al
    Variants in STXBP3 Are Associated With Very Early Onset Inflammatory Bowel Disease, Bilateral Sensorineural Hearing Loss and Immune Dysregulation.
    J Crohns Colitis. 2021 Apr 23. pii: 6247960. doi: 10.1093.
    PubMed     Abstract available


  307. SLEIMAN J, Hitawala AA, Cohen B, Falloon K, et al
    Systematic review: Sweet syndrome associated with inflammatory bowel disease.
    J Crohns Colitis. 2021 Apr 23. pii: 6247949. doi: 10.1093.
    PubMed     Abstract available


  308. UNTERWEGER AL, Jensen MO, Giordanetto F, Jogini V, et al
    Suppressing Kv1.3 Ion Channel Activity with a Novel Small Molecule Inhibitor Ameliorates Inflammation in a Humanized Mouse Model of Ulcerative Colitis.
    J Crohns Colitis. 2021 Apr 23. pii: 6247959. doi: 10.1093.
    PubMed     Abstract available


  309. PANES J, Vermeire S, Dubinsky MC, Loftus EV, et al
    Efficacy and Safety of Tofacitinib Retreatment for Ulcerative Colitis After Treatment Interruption: Results From the OCTAVE Clinical Trials.
    J Crohns Colitis. 2021 Apr 22. pii: 6245086. doi: 10.1093.
    PubMed     Abstract available


  310. CHAPARRO M, Garre A, Iborra M, Sierra M, et al
    Effectiveness and safety of ustekinumab in ulcerative colitis: Real-world evidence from the ENEIDA registry.
    J Crohns Colitis. 2021 Apr 16. pii: 6228235. doi: 10.1093.
    PubMed     Abstract available


  311. JUNG S, Ye BD, Lee HS, Baek J, et al
    Identification of three novel susceptibility loci for inflammatory bowel disease in Koreans in an extended genome-wide association study.
    J Crohns Colitis. 2021 Apr 14. pii: 6225940. doi: 10.1093.
    PubMed     Abstract available


  312. FUMERY M, Yzet C, Chatelain D, Yzet T, et al
    Colonic strictures in inflammatory bowel disease: epidemiology, complications, and management.
    J Crohns Colitis. 2021 Apr 12. pii: 6222697. doi: 10.1093.
    PubMed     Abstract available


  313. ATTAR A, Branche J, Coron E, Privat J, et al
    An Anti-migration Self-expandable and Removable Metal Stent for Crohn's Disease Strictures: A Nationwide Study From GETAID and SFED.
    J Crohns Colitis. 2021;15:521-528.
    PubMed     Abstract available


  314. NOVAK KL, Nylund K, Maaser C, Petersen F, et al
    Expert Consensus on Optimal Acquisition and Development of the International Bowel Ultrasound Segmental Activity Score [IBUS-SAS]: A Reliability and Inter-rater Variability Study on Intestinal Ultrasonography in Crohn's Disease.
    J Crohns Colitis. 2021;15:609-616.
    PubMed     Abstract available


  315. ZHAO J, Wang H, Zhou J, Qian J, et al
    miR-130a-3p, a Preclinical Therapeutic Target for Crohn's Disease.
    J Crohns Colitis. 2021;15:647-664.
    PubMed     Abstract available


  316. DE VRIES LCS, Ghiboub M, van Hamersveld PHP, Welting O, et al
    Tyrosine Kinase 2 Signalling Drives Pathogenic T cells in Colitis.
    J Crohns Colitis. 2021;15:617-630.
    PubMed     Abstract available


  317. CON D, Parthasarathy N, Bishara M, Luber RP, et al
    Development of a Simple, Serum Biomarker-based Model Predictive of the Need for Early Biologic Therapy in Crohn's Disease.
    J Crohns Colitis. 2021;15:583-593.
    PubMed     Abstract available


  318. HUGOT JP, Dumay A, Barreau F, Meinzer U, et al
    Crohn's Disease: Is the Cold Chain Hypothesis Still Hot?
    J Crohns Colitis. 2021;15:678-686.
    PubMed     Abstract available


  319. LUND K, Larsen MD, Knudsen T, Kjeldsen J, et al
    Infliximab, Immunomodulators and Treatment Failures in Paediatric and Adolescent Patients with Crohn's Disease: a Nationwide Cohort Study.
    J Crohns Colitis. 2021;15:575-582.
    PubMed     Abstract available


  320. VERSTOCKT B, Pouillon L, Bossuyt P
    Tofacitinib and Subacute Pneumonitis: Don't Hold Your Breath.
    J Crohns Colitis. 2021;15:692-693.
    PubMed    


  321. RUTKA M, Pigniczki D, Molnar T
    Tofacitinib Therapy, the Lender of Last Resort.
    J Crohns Colitis. 2021;15:694.
    PubMed    


  322. D'AMICO F, Guillo L, Baumann C, Danese S, et al
    Histological disease activity measured by the Nancy index is associated with long-term outcomes in patients with ulcerative colitis.
    J Crohns Colitis. 2021 Apr 5. pii: 6211061. doi: 10.1093.
    PubMed     Abstract available


  323. NG A
    Clinical efficacy of tofacitinib in moderate to severe ulcerative colitis.
    J Crohns Colitis. 2021 Apr 5. pii: 6211060. doi: 10.1093.
    PubMed    


    March 2021
  324. BRESSLER B, Yarur A, Silverberg MS, Bassel M, et al
    Vedolizumab and Anti-TNFalpha Real-World Outcomes in Biologic-Naive Inflammatory Bowel Disease Patients: Results from the EVOLVE Study.
    J Crohns Colitis. 2021 Mar 31. pii: 6205394. doi: 10.1093.
    PubMed     Abstract available


  325. LANG-SCHWARZ C, Angeloni M, Agaimy A, Atreya R, et al
    Validation of the "Inflammatory Bowel Disease - Distribution, Chronicity, Activity (IBD-DCA) Score" for Ulcerative Colitis and Crohn s disease.
    J Crohns Colitis. 2021 Mar 27. pii: 6196021. doi: 10.1093.
    PubMed     Abstract available


  326. PALMIERI C, Muller G, Kroesen AJ, Galata C, et al
    Perianal fistula-associated carcinoma in Crohn s disease: a multicenter retrospective case control study.
    J Crohns Colitis. 2021 Mar 27. pii: 6189787. doi: 10.1093.
    PubMed     Abstract available


  327. NORSA L, Berni Canani R, Duclaux-Loras R, Bequet E, et al
    Inflammatory bowel disease in patients with congenital chloride diarrhoea.
    J Crohns Colitis. 2021 Mar 26. pii: 6189668. doi: 10.1093.
    PubMed     Abstract available


  328. RUDDY J, Taft T, Keszthelyi D
    Gut-Brain Interactions in patients with Inflammatory Bowel Disease (IBD) and the role of Hypnotherapy in Managing Symptoms.
    J Crohns Colitis. 2021 Mar 18. pii: 6175701. doi: 10.1093.
    PubMed    


  329. TORRES J, Halfvarson J, Rodriguez-Lago I, Hedin CRH, et al
    Results of the Seventh Scientific Workshop of ECCO: Precision medicine in IBD- prediction and prevention of inflammatory bowel disease.
    J Crohns Colitis. 2021 Mar 17. pii: 6175312. doi: 10.1093.
    PubMed     Abstract available


  330. KUCHARZIK T, Ellul P, Greuter T, Rahier JF, et al
    ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease.
    J Crohns Colitis. 2021 Mar 17. pii: 6175313. doi: 10.1093.
    PubMed    


  331. PIOVANI D, Pansieri C, Kotha SRR, Piazza AC, et al
    Ethnic Differences in the Smoking-Related Risk of Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.
    J Crohns Colitis. 2021 Mar 15. pii: 6171987. doi: 10.1093.
    PubMed     Abstract available


  332. VERSTOCKT B, Verstockt S, Abdu Rahiman S, Ke BJ, et al
    Intestinal Receptor of SARS-CoV-2 in Inflamed IBD Tissue Seems Downregulated by HNF4A in Ileum and Upregulated by Interferon Regulating Factors in Colon.
    J Crohns Colitis. 2021;15:485-498.
    PubMed     Abstract available


  333. COLLARD MK, Benoist S, Maggiori L, Zerbib P, et al
    A Reappraisal of Outcome of Elective Surgery After Successful Non-Operative Management of an Intra-Abdominal Abscess Complicating Ileocolonic Crohn's Disease: A Subgroup Analysis of a Nationwide Prospective Cohort.
    J Crohns Colitis. 2021;15:409-418.
    PubMed     Abstract available


  334. RICCIUTO A, Mack DR, Huynh HQ, Jacobson K, et al
    Diagnostic Delay Is Associated With Complicated Disease and Growth Impairment in Paediatric Crohn's Disease.
    J Crohns Colitis. 2021;15:419-431.
    PubMed     Abstract available


  335. MOREAU J, Hammoudi N, Marthey L, Trang-Poisson C, et al
    Impact of an Education Programme on IBD Patients' Skills: Results of a Randomised Controlled Multicentre Study [ECIPE].
    J Crohns Colitis. 2021;15:432-440.
    PubMed     Abstract available


  336. NARULA N, Wong ECL, Dulai PS, Marshall JK, et al
    Week 6 Calprotectin Best Predicts Likelihood of Long-term Endoscopic Healing in Crohn's Disease: A Post-hoc Analysis of the UNITI/IM-UNITI Trials.
    J Crohns Colitis. 2021;15:462-470.
    PubMed     Abstract available


  337. BARELLO S, Guida E, Bonanomi A, Menichetti J, et al
    WE-CARE IBD SCORE: Assessing High-quality Care From the Perspective of Patients With Inflammatory Bowel Disease.
    J Crohns Colitis. 2021;15:349-357.
    PubMed     Abstract available


  338. WINTJENS D, Bergey F, Saccenti E, Jeuring S, et al
    Disease Activity Patterns of Crohn's Disease in the First Ten Years After Diagnosis in the Population-based IBD South Limburg Cohort.
    J Crohns Colitis. 2021;15:391-400.
    PubMed     Abstract available


  339. FOURIE S, Norton C, Jackson D, Czuber-Dochan W, et al
    'These discussions aren't happening'. Experiences of people living with inflammatory bowel disease talking about sexual well-being with healthcare professionals.
    J Crohns Colitis. 2021 Mar 4. pii: 6158978. doi: 10.1093.
    PubMed     Abstract available


  340. PAI RK, Hartman DJ, Leighton JA, Shabana PF, et al
    Validated Indices for Histopathologic Activity Predict Development of Colorectal Neoplasia in Ulcerative Colitis.
    J Crohns Colitis. 2021 Mar 4. pii: 6158975. doi: 10.1093.
    PubMed     Abstract available


  341. ATREYA R, Neurath MF
    Can Serum Proteomic Profiling Annunciate Individual Disease Progression in Newly Diagnosed Inflammatory Bowel Disease Patients?
    J Crohns Colitis. 2021 Mar 2. pii: 6156783. doi: 10.1093.
    PubMed    


    February 2021
  342. LUDVIGSSON JF, Olen O, Larsson H, Halfvarson J, et al
    Association between inflammatory bowel disease and psychiatric morbidity and suicide: A Swedish nationwide population-based cohort study with sibling comparisons.
    J Crohns Colitis. 2021 Feb 26. pii: 6153473. doi: 10.1093.
    PubMed     Abstract available


  343. GUILLO L, Peyrin-Biroulet L, Louis E
    Tofacitinib De-escalation Strategy in Ulcerative Colitis: Is It the End of the Story?
    J Crohns Colitis. 2021 Feb 23. pii: 6146725. doi: 10.1093.
    PubMed    


  344. ALLIN KH, Jacobsen RK, Ungaro RC, Colombel JF, et al
    Bariatric surgery and risk of new-onset inflammatory bowel disease: A nationwide cohort study.
    J Crohns Colitis. 2021 Feb 20. pii: 6145790. doi: 10.1093.
    PubMed     Abstract available


  345. GOETGEBUER RL, Kreijne JE, Aitken CA, Dijkstra G, et al
    Increased risk of high-grade cervical neoplasia in women with inflammatory bowel disease: a case-controlled cohort study.
    J Crohns Colitis. 2021 Feb 20. pii: 6145789. doi: 10.1093.
    PubMed     Abstract available


  346. REINISCH W, Sandborn WJ, Danese S, Hebuterne X, et al
    Long-term safety and efficacy of the anti-MAdCAM-1 monoclonal antibody ontamalimab (SHP647) for the treatment of ulcerative colitis: the open-label study TURANDOT II.
    J Crohns Colitis. 2021 Feb 18. pii: 6144575. doi: 10.1093.
    PubMed     Abstract available


  347. ARAKI T, Mitsuyama K, Yamasaki H, Morita M, et al
    Therapeutic Potential of a Self-Assembling Peptide Hydrogel to Treat Colonic Injuries Associated with Inflammatory Bowel Disease.
    J Crohns Colitis. 2021 Feb 17. pii: 6141509. doi: 10.1093.
    PubMed     Abstract available


  348. ACKERMANN M, Mucci A, McCabe A, Frei S, et al
    Restored macrophage function ameliorates disease pathophysiology in a mouse model for IL10 receptor deficient very early onset inflammatory bowel disease.
    J Crohns Colitis. 2021 Feb 17. pii: 6141466. doi: 10.1093.
    PubMed     Abstract available


  349. WATANABE S, Nishimura R, Shirasaki T, Katsukura N, et al
    Schlafen 11 is a novel target for mucosal regeneration in Ulcerative Colitis.
    J Crohns Colitis. 2021 Feb 17. pii: 6141476. doi: 10.1093.
    PubMed     Abstract available


  350. ZHAO M, Gonczi L, Lakatos PL, Burisch J, et al
    The burden of inflammatory bowel disease in Europe in 2020.
    J Crohns Colitis. 2021 Feb 14. pii: 6134782. doi: 10.1093.
    PubMed     Abstract available


  351. BARNES EL, Holubar SD, Herfarth HH
    Systematic Review and Meta-Analysis of Outcomes after Ileal Pouch-Anal Anastomosis in Primary Sclerosing Cholangitis-Ulcerative Colitis.
    J Crohns Colitis. 2021 Feb 5. pii: 6129144. doi: 10.1093.
    PubMed     Abstract available


  352. GHOSH S, Iacucci M
    Measuring Patient Experience in Inflammatory Bowel Disease Care: A Key Component of Continuous Quality Improvement.
    J Crohns Colitis. 2021 Feb 5. pii: 6129099. doi: 10.1093.
    PubMed    


    January 2021
  353. RUIGROK RAAA, Collij V, Sureda P, Klaassen MAY, et al
    The composition and metabolic potential of the human small intestinal microbiota within the context of inflammatory bowel disease.
    J Crohns Colitis. 2021 Jan 30. pii: 6123997. doi: 10.1093.
    PubMed     Abstract available


  354. GRIM C, Noble R, Uribe G, Khanipov K, et al
    Impairment of tissue resident mesenchymal stem cells in chronic ulcerative colitis and Crohn's disease.
    J Crohns Colitis. 2021 Jan 28. pii: 6121690. doi: 10.1093.
    PubMed     Abstract available


  355. ALLOCCA M, Bonovas S, Danese S
    Letter to the Editor Intestinal Ultrasound to Assess Disease Activity in Ulcerative Colitis: Development of a novel UC-Ultrasound index.
    J Crohns Colitis. 2021 Jan 25. pii: 6119566. doi: 10.1093.
    PubMed    


  356. LOVE BL, Finney CJ, Gaidos JKJ
    Effectiveness of Conjugate and Polysaccharide Pneumococcal Vaccines for Prevention of Severe Pneumococcal Disease Among Inflammatory Bowel Disease Patients.
    J Crohns Colitis. 2021 Jan 25. pii: 6118663. doi: 10.1093.
    PubMed     Abstract available


  357. VERMEIRE S, Chiorean M, Panes J, Peyrin-Biroulet L, et al
    Long-term Safety and Efficacy of Etrasimod for Ulcerative Colitis: Results from the Open-label Extension of the OASIS Study.
    J Crohns Colitis. 2021 Jan 21. pii: 6105062. doi: 10.1093.
    PubMed     Abstract available


  358. ZAIATZ BITTENCOURT V, Jones F, Tosetto M, Doherty GA, et al
    Dysregulation of metabolic pathways in circulating natural killer cells isolated from inflammatory bowel disease patients.
    J Crohns Colitis. 2021 Jan 18. pii: 6103919. doi: 10.1093.
    PubMed     Abstract available


  359. SANDBORN WJ, Feagan BG, Hanauer S, Vermeire S, et al
    Long-Term Efficacy And Safety Of Ozanimod In Moderate-To-Severe Ulcerative Colitis: Results From The Open-Label Extension Of The Randomized, Phase 2 Touchstone Study.
    J Crohns Colitis. 2021 Jan 13. pii: 6092404. doi: 10.1093.
    PubMed     Abstract available


  360. EFFENBERGER M, Reider S, Waschina S, Bronowski C, et al
    Microbial Butyrate Synthesis Indicates Therapeutic Efficacy of Azathioprine in IBD Patients.
    J Crohns Colitis. 2021;15:88-98.
    PubMed     Abstract available


  361. LEE S, Kuenzig ME, Ricciuto A, Zhang Z, et al
    Smoking May Reduce the Effectiveness of Anti-TNF Therapies to Induce Clinical Response and Remission in Crohn's Disease: A Systematic Review and Meta-analysis.
    J Crohns Colitis. 2021;15:74-87.
    PubMed     Abstract available


  362. THOMAS PWA, Ferwerda G, West RL, Hoentjen F, et al
    Immediate Infusion Reaction to Intravenous Ustekinumab in Three Crohn's Disease Patients: A Case Report and Review of the Literature.
    J Crohns Colitis. 2021;15:162-164.
    PubMed     Abstract available


  363. WEWER MD, Zhao M, Nordholm-Carstensen A, Weimers P, et al
    The Incidence and Disease Course of Perianal Crohn's Disease: A Danish Nationwide Cohort Study, 1997-2015.
    J Crohns Colitis. 2021;15:5-13.
    PubMed     Abstract available


  364. DE CAMPOS RJDS, Lucchetti G, Lucchetti ALG, Chebli LA, et al
    Influence of Religiousness and Spirituality on Remission Rate, Mental Health, and Quality of Life of Patients With Active Crohn's Disease: A Longitudinal 2-Year Follow-up Study.
    J Crohns Colitis. 2021;15:55-63.
    PubMed     Abstract available


  365. ZOLLNER A, Schmiderer A, Reider SJ, Oberhuber G, et al
    Faecal Biomarkers in Inflammatory Bowel Diseases: Calprotectin Versus Lipocalin-2-a Comparative Study.
    J Crohns Colitis. 2021;15:43-54.
    PubMed     Abstract available


  366. SAEVIK F, Eriksen R, Eide GE, Gilja OH, et al
    Development and Validation of a Simple Ultrasound Activity Score for Crohn's Disease.
    J Crohns Colitis. 2021;15:115-124.
    PubMed     Abstract available


  367. D'AMICO F, Nancey S, Danese S, Peyrin-Biroulet L, et al
    A Practical Guide for Faecal Calprotectin Measurement: Myths and Realities.
    J Crohns Colitis. 2021;15:152-161.
    PubMed     Abstract available


  368. KUCHARZIK T, Maaser C, Maconi G
    A Simple Intestinal Ultrasound Score in Crohn's Disease: First Big Step Towards New Paradigms.
    J Crohns Colitis. 2021;15:3-4.
    PubMed    


  369. MAASER C, Kucharzik T, Gecse K
    Is Intestinal Ultrasound Ready to be Used as Standard Monitoring Tool in Daily Practice and as Endpoint in Clinical Trials?
    J Crohns Colitis. 2021;15:1-2.
    PubMed    


  370. DAI C, Jiang M, Huang YH
    Anti-Tubercular Therapy on the Long-Term Disease Course of Patients with Crohn's disease.
    J Crohns Colitis. 2021;15:169.
    PubMed    


  371. BARBERIO B, Segal JP, Quraishi MN, Black CJ, et al
    Efficacy of Oral, Topical, or Combined Oral and Topical 5-Aminosalicylates, in Ulcerative Colitis: Systematic Review and Network Meta-Analysis.
    J Crohns Colitis. 2021 Jan 12. pii: 6089122. doi: 10.1093.
    PubMed     Abstract available


  372. DE VOOGD F, Wilkens R, Gecse K, Allocca M, et al
    A reliability study - strong inter-observer agreement of an expert panel for intestinal ultrasound in ulcerative colitis.
    J Crohns Colitis. 2021 Jan 9. pii: 6073674. doi: 10.1093.
    PubMed     Abstract available


  373. BOTS S, Nylund K, Lowenberg M, Gecse K, et al
    Intestinal Ultrasound to Assess Disease Activity in Ulcerative Colitis: Development of a novel UC-Ultrasound index.
    J Crohns Colitis. 2021 Jan 7. pii: 6067606. doi: 10.1093.
    PubMed     Abstract available


    December 2020
  374. VAN DER SLOOT KWJ, Voskuil MD, Blokzijl T, Dinkla A, et al
    Isotype specific antibody responses to Mycobacterium Avium subspecies Paratuberculosis antigens are associated with the use of biological therapy in Inflammatory Bowel Disease.
    J Crohns Colitis. 2020 Dec 30. pii: 6055607. doi: 10.1093.
    PubMed     Abstract available


  375. GUILLO L, D'Amico F, Danese S, Peyrin-Biroulet L, et al
    Ustekinumab for extra-intestinal manifestations of inflammatory bowel disease: a systematic literature review.
    J Crohns Colitis. 2020 Dec 24. pii: 6046385. doi: 10.1093.
    PubMed     Abstract available


  376. CROUWEL F, Waaijenberg-Warmenhoven P, Buiter HJC, de Boer NK, et al
    Recurrent COVID-19 in a patient with ulcerative colitis on vedolizumab therapy.
    J Crohns Colitis. 2020 Dec 22. pii: 6044002. doi: 10.1093.
    PubMed    


  377. RAHMI G, Coron E, Perrod G, Levy M, et al
    Probe-based confocal laser endomicroscopy for in vivo assessment of histological healing in ulcerative colitis: development and validation of the ENHANCE index.
    J Crohns Colitis. 2020 Dec 18. pii: 6041240. doi: 10.1093.
    PubMed     Abstract available


  378. BANCIL AS, Sandall AM, Rossi M, Chassaing B, et al
    Food additive emulsifiers and their impact on gut microbiome, permeability and inflammation: mechanistic insights in inflammatory bowel disease.
    J Crohns Colitis. 2020 Dec 18. pii: 6041235. doi: 10.1093.
    PubMed     Abstract available


  379. VENTIN-HOLMBERG R, Eberl A, Saqib S, Korpela K, et al
    Bacterial and fungal profiles as markers of infliximab drug response in inflammatory bowel disease.
    J Crohns Colitis. 2020 Dec 10. pii: 6029424. doi: 10.1093.
    PubMed     Abstract available


  380. VERMEIRE S, Su C, Lawendy N, Kobayashi T, et al
    Outcomes of Tofacitinib Dose Reduction in Patients with Ulcerative Colitis in Stable Remission from the Randomized RIVETING Trial.
    J Crohns Colitis. 2020 Dec 8. pii: 6027842. doi: 10.1093.
    PubMed     Abstract available


  381. MONSTAD IL, Solberg IC, Cvancarova M, Hovde O, et al
    Outcome of Ulcerative Colitis 20 Years after Diagnosis in a Prospective Population-based Inception Cohort from South-Eastern Norway, the IBSEN Study.
    J Crohns Colitis. 2020 Dec 2. pii: 6015889. doi: 10.1093.
    PubMed     Abstract available


    November 2020
  382. JOHNSON LE, Lee MJ, Turner-Moore T, Grinsted Tate LR, et al
    Systematic review of factors affecting transition readiness skills in patients with inflammatory bowel disease.
    J Crohns Colitis. 2020 Nov 30. pii: 6012510. doi: 10.1093.
    PubMed     Abstract available


  383. HAMAMA-RAZ Y, Nativ S, Hamama L
    Posttraumatic Growth in Inflammatory Bowel Disease Patients: The Role of Illness Cognitions and Physical Quality in Life.
    J Crohns Colitis. 2020 Nov 30. pii: 6012764. doi: 10.1093.
    PubMed     Abstract available


  384. TADBIRI S, Nachury M, Bouhnik Y, Serrero M, et al
    The IBD-disk is a reliable tool to assess the daily-life burden of patients with inflammatory bowel disease.
    J Crohns Colitis. 2020 Nov 27. pii: 6007776. doi: 10.1093.
    PubMed     Abstract available


  385. WINTHROP KL, Loftus EV Jr, Baumgart DC, Reinisch W, et al
    Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Infection Rates from the Ulcerative Colitis Clinical Programme.
    J Crohns Colitis. 2020 Nov 27. pii: 6007683. doi: 10.1093.
    PubMed     Abstract available


  386. VAN DEN BERGHE N, Verstockt B, Gils A, Sabino J, et al
    Tissue exposure does not explain non-response in ulcerative colitis patients with adequate serum vedolizumab concentrations.
    J Crohns Colitis. 2020 Nov 27. pii: 6007493. doi: 10.1093.
    PubMed     Abstract available


  387. EVERHOV AH, Bruze G, Soderling J, Askling J, et al
    Women's earnings are more affected by inflammatory bowel disease than men's: a register-based Swedish cohort study.
    J Crohns Colitis. 2020 Nov 27. pii: 6007494. doi: 10.1093.
    PubMed     Abstract available


  388. HOEKMAN DR, Vlieger AM, Stokkers PC, Mahhmod N, et al
    Hypnotherapy for irritable bowel syndrome-type symptoms in patients with quiescent inflammatory bowel disease: a randomized, controlled trial.
    J Crohns Colitis. 2020 Nov 27. pii: 6007495. doi: 10.1093.
    PubMed     Abstract available


  389. AGRAWAL M, Brenner EJ, Zhang X, Colombel JF, et al
    Physician practice patterns on holding inflammatory bowel disease medications due to COVID-19 in the SECURE-IBD registry.
    J Crohns Colitis. 2020 Nov 24. pii: 6000079. doi: 10.1093.
    PubMed     Abstract available


  390. TRAN-MINH ML, Gornet JM, Maillet M, Houze P, et al
    Safety of hydrocortisone premedication discontinuation in patients with inflammatory bowel disease on maintenance therapy with Infliximab: a prospective clinical and pharmacological study.
    J Crohns Colitis. 2020 Nov 18. pii: 5986749. doi: 10.1093.
    PubMed     Abstract available


  391. KALLA R, Adams AT, Bergemalm D, Vatn S, et al
    Serum proteomic profiling at diagnosis predicts clinical course, and need for intensification of treatment in inflammatory bowel disease.
    J Crohns Colitis. 2020 Nov 17. pii: 5985635. doi: 10.1093.
    PubMed     Abstract available


  392. GALLAGHER K, Catesson A, Griffin JL, Holmes E, et al
    Metabolomic Analysis in Inflammatory Bowel Disease: A Systematic Review.
    J Crohns Colitis. 2020 Nov 11. pii: 5974408. doi: 10.1093.
    PubMed     Abstract available


  393. KIM MA, Kim YH, Chun J, Lee HS, et al
    The influence of disease activity on pregnancy outcomes in women with inflammatory bowel disease: A systematic review and meta-analysis.
    J Crohns Colitis. 2020 Nov 11. pii: 5974276. doi: 10.1093.
    PubMed     Abstract available


  394. BARBERIO B, Black CJ, Savarino EV, Ford AC, et al
    Ciclosporin or Infliximab as Rescue Therapy in Acute Glucorticosteroid-refractory Ulcerative Colitis: Systematic Review and Network Meta-Analysis.
    J Crohns Colitis. 2020 Nov 11. pii: 5974124. doi: 10.1093.
    PubMed     Abstract available


  395. SEBASTIAN S, Gonzalez HA, Peyrin-Biroulet L
    Safety of Drugs During Previous and Current Coronavirus Pandemics: Lessons for Inflammatory Bowel Disease.
    J Crohns Colitis. 2020;14:1632-1643.
    PubMed     Abstract available


  396. TURSI A, Papa A
    Impact of Anti-TNFalpha Antibodies on the Risk of Covid-19 and its Severity in Patients with Inflammatory Bowel Diseases.
    J Crohns Colitis. 2020;14:1646-1647.
    PubMed    


  397. VOSKUIL MD, Spekhorst LM, van der Sloot KWJ, Jansen BH, et al
    Genetic risk scores identify genetic aetiology of inflammatory bowel disease phenotypes.
    J Crohns Colitis. 2020 Nov 6. pii: 5957220. doi: 10.1093.
    PubMed     Abstract available


  398. YOKOYAMA Y, Sawada K, Aoyama N, Yoshimura N, et al
    Erratum to: Efficacy of Granulocyte and Monocyte Adsorptive Apheresis in Patients With Inflammatory Bowel Disease Showing Lost Response to Infliximab.
    J Crohns Colitis. 2020 Nov 6. pii: 5958727. doi: 10.1093.
    PubMed    


    October 2020
  399. MAHMOUD R, van Lieshout C, Frederix GWJ, Jharap B, et al
    Continuation of anti-TNF in patients with Ulcerative Colitis in Remission is not Cost-effective compared to Treatment Withdrawal: a Markov Model.
    J Crohns Colitis. 2020 Oct 30. pii: 5944009. doi: 10.1093.
    PubMed     Abstract available


  400. SIEGEL CA, Christensen B, Kornbluth A, Rosh JR, et al
    Guidance for Restarting Inflammatory Bowel Disease Therapy in Patients Who Withheld Immunosuppressant Medications During COVID-19.
    J Crohns Colitis. 2020;14.
    PubMed     Abstract available


  401. LEWIN S, Lees C, Regueiro M, Hart A, et al
    International Organization for the Study of Inflammatory Bowel Disease: Global Strategies for Telemedicine and Inflammatory Bowel Diseases.
    J Crohns Colitis. 2020;14.
    PubMed     Abstract available


  402. DE LIMA-KARAGIANNIS A, Juillerat P, Sebastian S, Pedersen N, et al
    Management of Pregnant Inflammatory Bowel Disease Patients During the COVID-19 Pandemic.
    J Crohns Colitis. 2020;14.
    PubMed     Abstract available


  403. ABREU MT, Peyrin-Biroulet L
    Providing Guidance During a Global Viral Pandemic for the Care of Patients With Inflammatory Bowel Disease.
    J Crohns Colitis. 2020;14.
    PubMed    


  404. NG SC, Mak JWY, Hitz L, Chowers Y, et al
    COVID-19 Pandemic: Which IBD Patients Need to Be Scoped-Who Gets Scoped Now, Who Can Wait, and how to Resume to Normal.
    J Crohns Colitis. 2020;14.
    PubMed     Abstract available


  405. DOTAN I, Panaccione R, Kaplan GG, O'Morain C, et al
    Best Practice Guidance for Adult Infusion Centres during the COVID-19 Pandemic: Report from the COVID-19 International Organization for the Study of IBD [IOIBD] Task Force.
    J Crohns Colitis. 2020;14.
    PubMed     Abstract available


  406. ALLEZ M, Fleshner P, Gearry R, Lakatos PL, et al
    Care of the Patient With IBD Requiring Hospitalisation During the COVID-19 Pandemic.
    J Crohns Colitis. 2020;14.
    PubMed     Abstract available


  407. QURAISHI MN, Iqbal TH, Hart AL
    Precision Medicine with FMT for Ulcerative Colitis: Are We There Yet?
    J Crohns Colitis. 2020 Oct 20. pii: 5932516. doi: 10.1093.
    PubMed    


  408. DERIKX LAAP, Lantinga MA, de Jong DJ, van Dop WA, et al
    Clinical Outcomes of Covid-19 in Patients with Inflammatory Bowel Disease: A Nationwide Cohort Study.
    J Crohns Colitis. 2020 Oct 20. pii: 5932316. doi: 10.1093.
    PubMed     Abstract available


  409. BOSSUYT P, Bisschops R, Vermeire S, De Hertogh G, et al
    Variability in the distribution of histological disease activity in the colon of patients with ulcerative colitis.
    J Crohns Colitis. 2020 Oct 14. pii: 5923369. doi: 10.1093.
    PubMed     Abstract available


  410. ATTAUABI M, Poulsen A, Theede K, Pedersen N, et al
    Prevalence and outcomes of COVID-19 among patients with inflammatory bowel disease - A Danish prospective population-based cohort study.
    J Crohns Colitis. 2020 Oct 9. pii: 5920382. doi: 10.1093.
    PubMed     Abstract available


  411. ALOI M, Bramuzzo M, Norsa L, Arrigo S, et al
    Disease activity patterns in the first 5 years after diagnosis in children with ulcerative colitis: a population-based study.
    J Crohns Colitis. 2020 Oct 6. pii: 5918427. doi: 10.1093.
    PubMed     Abstract available


    September 2020
  412. MEREDITH J, Khedim CA, Henderson P, Wilson DC, et al
    Paediatric Inflammatory Multisystem Syndrome temporally associated with SARS-CoV-2 (PIMS-TS) in a patient receiving Infliximab therapy for Inflammatory Bowel Disease.
    J Crohns Colitis. 2020 Sep 30. pii: 5913452. doi: 10.1093.
    PubMed     Abstract available


  413. ARHI C, Askari A, Nachiappan S, Bottle A, et al
    Stage at diagnosis and survival of colorectal cancer with or without underlying inflammatory bowel disease: a population-based study.
    J Crohns Colitis. 2020 Sep 29. pii: 5912977. doi: 10.1093.
    PubMed     Abstract available


    June 2020
  414. D'AMICO F, Baumann C, Rousseau H, Danese S, et al
    Phase I, II and III Trials in Inflammatory Bowel Diseases: A Practical Guide for the Non-specialist.
    J Crohns Colitis. 2020;14:710-718.
    PubMed     Abstract available


  415. SOMERS M, Bossuyt P, Ferrante M, Peeters H, et al
    Belgian IBD Research Group [BIRD] Position Statement 2019 on the Use of Adalimumab Biosimilars in Inflammatory Bowel Diseases.
    J Crohns Colitis. 2020;14:680-685.
    PubMed     Abstract available


  416. VON MARTELS JZH, Bourgonje AR, Klaassen MAY, Alkhalifah HAA, et al
    Riboflavin Supplementation in Patients with Crohn's Disease [the RISE-UP study].
    J Crohns Colitis. 2020;14:595-607.
    PubMed     Abstract available


  417. FAUNY M, D'Amico F, Bonovas S, Netter P, et al
    Faecal Calprotectin for the Diagnosis of Bowel Inflammation in Patients With Rheumatological Diseases: A Systematic Review.
    J Crohns Colitis. 2020;14:688-693.
    PubMed     Abstract available


  418. ZHOU C, Wu XR, Liu HS, Liu XH, et al
    Immunomodulatory Effect of Urine-derived Stem Cells on Inflammatory Bowel Diseases via Downregulating Th1/Th17 Immune Responses in a PGE2-dependent Manner.
    J Crohns Colitis. 2020;14:654-668.
    PubMed     Abstract available


  419. VALE RODRIGUES R, Sladek M, Katsanos K, van der Woude CJ, et al
    Diagnosis and Outcome of Oesophageal Crohn's Disease.
    J Crohns Colitis. 2020;14:624-629.
    PubMed     Abstract available


  420. AL NABHANI Z, Berrebi D, Martinez-Vinson C, Montcuquet N, et al
    Nod2 Protects the Gut From Experimental Colitis Spreading to Small Intestine.
    J Crohns Colitis. 2020;14:669-679.
    PubMed     Abstract available


  421. ZHAO M, Burisch J
    The Sooner the Better? Cost-effectiveness of Early Biological Therapy in Patients With Crohn's Disease.
    J Crohns Colitis. 2020;14:573-574.
    PubMed    


  422. EDER P, Dobrowolska A, Rydzewska G
    Historical Upheavals and Eponyms in Crohn's Disease-Is There Any Relation?
    J Crohns Colitis. 2020;14:719.
    PubMed    


    May 2020
  423. NEHRA AK, Sheedy SP, Wells ML, VanBuren WM, et al
    Imaging Findings of Ileal Inflammation at Computed Tomography and Magnetic Resonance Enterography: What do They Mean When Ileoscopy and Biopsy are Negative?
    J Crohns Colitis. 2020;14:455-464.
    PubMed     Abstract available


  424. DANIELOU M, Sarter H, Pariente B, Fumery M, et al
    Natural History of Perianal Fistulising Lesions in Patients With Elderly-onset Crohn's Disease: A Population-based Study.
    J Crohns Colitis. 2020;14:501-507.
    PubMed     Abstract available


  425. PILLAI N, Lupatsch JE, Dusheiko M, Schwenkglenks M, et al
    Evaluating the Cost-Effectiveness of Early Compared with Late or No Biologic Treatment to Manage Crohn's Disease using Real-World Data.
    J Crohns Colitis. 2020;14:490-500.
    PubMed     Abstract available


  426. CONDAMINA M, Diaz E, Jamart C, Loget J, et al
    Severe Attack of Henoch-Schonlein Purpura With Neurological Involvement During Adalimumab Treatment for Crohn's Disease.
    J Crohns Colitis. 2020;14:538-542.
    PubMed     Abstract available


  427. SPARROW MP, Papamichael K, Ward MG, Riviere P, et al
    Therapeutic Drug Monitoring of Biologics During Induction to Prevent Primary Non-Response.
    J Crohns Colitis. 2020;14:542-556.
    PubMed     Abstract available


  428. RODRIGUEZ-LAGO I, Gisbert JP
    The Role of Immunomodulators and Biologics in the Medical Management of Stricturing Crohn's Disease.
    J Crohns Colitis. 2020;14:557-566.
    PubMed     Abstract available


  429. DHALIWAL J, Walters TD, Mack DR, Huynh HQ, et al
    Phenotypic Variation in Paediatric Inflammatory Bowel Disease by Age: A Multicentre Prospective Inception Cohort Study of the Canadian Children IBD Network.
    J Crohns Colitis. 2020;14:445-454.
    PubMed     Abstract available


  430. MADARAME A, Kimura H, Kunisaki R
    Successful Treatment With Ustekinumab for Enterocutaneous Fistulas in Crohn's Disease.
    J Crohns Colitis. 2020;14:569-570.
    PubMed    


  431. CHATEAU T, Angioi K, Peyrin-Biroulet L
    Two Cases of Successful Ustekinumab Treatment for Non-infectious Uveitis Associated With Crohn's Disease.
    J Crohns Colitis. 2020;14:571.
    PubMed    


    March 2020
  432. ANNESE V
    Small Bowel Adenocarcinoma in Crohn's Disease: An Underestimated Risk?
    J Crohns Colitis. 2020;14:285-286.
    PubMed    


  433. CARBONNEL F, Svrcek M
    Progress in the Molecular and Histological Dissection of Crohn's Disease-associated Small Bowel Adenocarcinomas.
    J Crohns Colitis. 2020;14:283-284.
    PubMed    


  434. DELATTRE C, Lewis A, Kirchgesner J, Nion-Larmurier I, et al
    Impact of Aphthous Colitis at Diagnosis on Crohn's Disease Outcomes.
    J Crohns Colitis. 2020;14:342-350.
    PubMed     Abstract available


  435. FELWICK RK, Dingley GJR, Martinez-Nunez R, Sanchez-Elsner T, et al
    MicroRNA23a Overexpression in Crohn's Disease Targets Tumour Necrosis Factor Alpha Inhibitor Protein 3, Increasing Sensitivity to TNF and Modifying the Epithelial Barrier.
    J Crohns Colitis. 2020;14:381-392.
    PubMed     Abstract available


  436. FIELDS AC, Hu FY, Lu P, Irani J, et al
    Small Bowel Adenocarcinoma: Is There a Difference in Survival for Crohn's Versus Sporadic Cases?
    J Crohns Colitis. 2020;14:303-308.
    PubMed     Abstract available


  437. BORREN NZ, Tan W, Colizzo FP, Luther J, et al
    Longitudinal Trajectory of Fatigue With Initiation of Biologic Therapy in Inflammatory Bowel Diseases: A Prospective Cohort Study.
    J Crohns Colitis. 2020;14:309-315.
    PubMed     Abstract available


  438. PIOVANI D, Danese S, Peyrin-Biroulet L, Bonovas S, et al
    Environmental, Nutritional, and Socioeconomic Determinants of IBD Incidence: A Global Ecological Study.
    J Crohns Colitis. 2020;14:323-331.
    PubMed     Abstract available


  439. FRANZE E, Monteleone I, Laudisi F, Rizzo A, et al
    Cadherin-11 Is a Regulator of Intestinal Fibrosis.
    J Crohns Colitis. 2020;14:406-417.
    PubMed     Abstract available


  440. VERSTOCKT B, Mertens E, Dreesen E, Outtier A, et al
    Influence of Drug Exposure on Vedolizumab-Induced Endoscopic Remission in Anti-Tumour Necrosis Factor [TNF] Naive and Anti-TNF Exposed IBD Patients.
    J Crohns Colitis. 2020;14:332-341.
    PubMed     Abstract available


  441. POREDSKA K, Kunovsky L, Marek F, Kala Z, et al
    The Influence of Microscopic Inflammation at Resection Margins on Early Postoperative Endoscopic Recurrence After Ileocaecal Resection for Crohn's Disease.
    J Crohns Colitis. 2020;14:361-368.
    PubMed     Abstract available


  442. ARPA G, Grillo F, Giuffrida P, Nesi G, et al
    Separation of Low- Versus High-grade Crohn's Disease-associated Small Bowel Carcinomas is Improved by Invasive Front Prognostic Marker Analysis.
    J Crohns Colitis. 2020;14:295-302.
    PubMed     Abstract available


  443. PELLINO G, Vinci D, Signoriello G, Kontovounisios C, et al
    Long-Term Bowel Function and Fate of the Ileal Pouch After Restorative Proctocolectomy in Patients With Crohn's Disease: A Systematic Review With Meta-Analysis and Metaregression.
    J Crohns Colitis. 2020;14:418-427.
    PubMed     Abstract available


  444. LIAO X, Li G, McBride R, Houldsworth J, et al
    Clinicopathological and Molecular Characterisation of Crohn's Disease-associated Small Bowel Adenocarcinomas.
    J Crohns Colitis. 2020;14:287-294.
    PubMed     Abstract available


    February 2020
  445. ADAMINA M, Bonovas S, Raine T, Spinelli A, et al
    ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment.
    J Crohns Colitis. 2020;14:155-168.
    PubMed     Abstract available


  446. MAGRO F, Lopes J, Borralho P, Lopes S, et al
    Comparing the Continuous Geboes Score With the Robarts Histopathology Index: Definitions of Histological Remission and Response and their Relation to Faecal Calprotectin Levels.
    J Crohns Colitis. 2020;14:169-175.
    PubMed     Abstract available


  447. WASMANN KA
    Complications While Waiting for IBD Surgery-Short Report.
    J Crohns Colitis. 2020;14:277-280.
    PubMed     Abstract available


  448. KEITA AV, Alkaissi LY, Holm EB, Heil SDS, et al
    Enhanced E. coli LF82 Translocation through the Follicle-associated Epithelium in Crohn's Disease is Dependent on Long Polar Fimbriae and CEACAM6 expression, and Increases Paracellular Permeability.
    J Crohns Colitis. 2020;14:216-229.
    PubMed     Abstract available


  449. AGRAWAL M, Burisch J, Colombel JF, C Shah S, et al
    Viewpoint: Inflammatory Bowel Diseases Among Immigrants From Low- to High-Incidence Countries: Opportunities and Considerations.
    J Crohns Colitis. 2020;14:267-273.
    PubMed     Abstract available


  450. PIERRE N, Salee C, Massot C, Bletard N, et al
    Proteomics Highlights Common and Distinct Pathophysiological Processes Associated with Ileal and Colonic Ulcers in Crohn's Disease.
    J Crohns Colitis. 2020;14:205-215.
    PubMed     Abstract available


  451. COSTA-MOREIRA P, Lopes S, Santos AL, Pedrosa AF, et al
    Leukocytoclastic Vasculitis Related to Ustekinumab in a Crohn's Disease Patient: First Case Report and Literature Review.
    J Crohns Colitis. 2020;14:274-276.
    PubMed     Abstract available


    January 2020
  452. TORRES J, Bonovas S, Doherty G, Kucharzik T, et al
    ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment.
    J Crohns Colitis. 2020;14:4-22.
    PubMed    


  453. TRAVIS S
    IM-UNITI at Three Years: Stellar Stelara(R) or Stardust? The Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease.
    J Crohns Colitis. 2020;14:1-3.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Inflammatory Bowel Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: